LinkedIn




Hot Topics


Governor Cuomo Announces Series of Groundbreaking New Initiatives to End the AIDS Epidemic in NYS (12-1-16)

Posted December 1, 2016

Please see important press release; Governor Andrew M. Cuomo today announced a series of groundbreaking new initiatives in the fight against AIDS – building on the state’s successful blueprint to end the epidemic by the end of 2020.

http://www.governor.ny.gov/news/governor-cuomo-announces-series-groundbreaking-new-initiatives-end-aids-epidemic-new-york-state

 

^ Return to Top


NYS Medicaid Update: November (11-30-2016)

Posted November 30, 2016

Dear Medicaid Provider,

The Office of Health Insurance Programs of the New York State Department of Health has approved the release of the November 2016 Medicaid Update. Please find the full current issue as a PDF (Portable Document Format) file available to be downloaded at: http://www.health.ny.gov/health_care/medicaid/program/update/2016/nov16_mu.pdf

 

^ Return to Top


Great American Smokeout Dear Colleague Letter (11-17-2016)

Posted November 17, 2016

We are all aware of the increased dangers of smoking with HIV. Smoking increases the incidence of AIDS-related and non-AIDS related illnesses including cardiovascular disease, bacterial pneumonia, chronic obstructive pulmonary disease, lung cancer, head and neck cancer, and cervical and anal cancers. Yet, people living with HIV smoke at rates 2-3 times higher than the general population. Tobacco kills, especially people living with HIV. HIV+ smokers lose over six years of life expectancy from smoking, more than the HIV infection itself. But quitting saves lives. Research indicates that smoking cessation among HIV-positive smokers could decrease the risk of overall mortality by 16%.

Please make November 17, 2016, the Great American Smokeout, a community-wide day to quit tobacco!

Here’s what you can do:

  • Display Great American Smokeout poster in your waiting room, exam rooms and/or other common areas.
  • Speak to your patients about tobacco cessation, including working together to develop a quit plan and providing helpful resources.
  • Spread the word about the Great American Smokeout (see link above) and invite everyone to participate.

In addition, please stay tuned to the January 2017 launch of the AIDS Institute’s HIV Tobacco Cessation Quality Improvement Campaign. We look forward to working together on tobacco cessation for the HIV/AIDS community. Please contact Kelly.Hancock@health.ny.gov with any questions.

Click here to download a PDF of this letter.

The NYSDOH AIDS Institute guidelines Smoking Cessation in HIV-Infected Patients, is available online.

 

^ Return to Top


OMD Screenshot (11-16-2016)

Posted November 16, 2016

OMD SCREENSHOT – November 16, 2016

  • The 2017 NYS HIV Quality of Care Review will begin in early 2017 with a deadline for submission of March 31, 2017. Facilities will be expected to create organizational HIV treatment cascades. They will also be expected to submit data on VLS, ART, and STI indicators, as well as data on smoking cessation and stigma reduction efforts. For more information, contact Dan Belanger at daniel.belanger@health.ny.gov.
  • The Great American Smokeout, a nationwide smoking cessation initiative, will be held this Thursday, November 17, 2016. For tools and resources, visit the American Cancer Society webpage.
  • OMD is requesting applications for a clinical STI consultant to work closely with the Office of the Medical Director. For more information, including details on scope of work, please see the New York State Contract Reporter.
  • NYSDOH and NYCDOHMH issued a joint letter describing a recent case of breakthrough HIV infection in a NYC patient adherent to PrEP.
  • NYSDOH AIDS Institute is now accepting applications for the 2017 Viral Load Suppression QI Contest, with a deadline for submission of January 15, 2017. The aim of the contest is to showcase exemplary QI projects that improve VLS. For more information, contact Dan Belanger at daniel.belanger@health.ny.gov.

 

^ Return to Top


CEI Newsletter (11-15-2016)

Posted November 15, 2016

To view the latest update from the New York State Clinical Education Initiative, please click here.

Included are updates on the following:

 

^ Return to Top


Updates from AETC Program Friends & Colleagues (11-14-2016)

Posted November 14, 2016

Updates from AETC Program Friends & Colleagues are now available by clicking here.

Included are updates on the following:

 

^ Return to Top


Selzentry Approved for Pediatric Use (11-11-2016)

Posted November 11, 2016

On Friday November 4, 2016, FDA approved Selzentry (maraviroc) 20 mg/mL oral solution, Selzentry (maraviroc) 25 mg and 75 mg tablets and updated the label to include use in pediatric patients 2 years of age and older weighing at least 10 kg. The major changes to the label are summarized here.

 

^ Return to Top


Information About Recent Cases of HIV Infection Among Two People Taking PrEP (11-7-2016)

Posted November 7, 2016

The following resources from the NYSDOH and NYCDOHMH are available regarding a recent case of breakthrough HIV infection occurring in a man who was adherent to PrEP (Pre-Exposure Prophylaxis).

 

^ Return to Top


Updates from AETC Program Friends & Colleagues (11-7-2016)

Posted November 7, 2016

Updates from AETC Program Friends & Colleagues are now available by clicking here.

Included are updates on the following:

 

^ Return to Top


NQC Learning Exchange Newsletter: end+disparities Learning Exchange (11-7-2016)

Posted November 7, 2016

The Learning Exchange aligns with the National HIV/AIDS Strategy, involves Ryan White HIV/AIDS Program recipients across all funding streams, and links participants to leading disparity and quality improvement experts. Learn more about the Learning Exchange here. So much of what you do with disparities will start with measurement, because you will need to know where to start!

Join us for our November Webinar to learn more about how to measure disparities and discuss ways you can use these tools and methods at your organization.

Setting Baseline Disparity Data
Thursday, November 17
1-2 pm ET
Register at this link!

This month, we are also introducing Partners in+care, the consumer involvement mechanism in end+disparities Learning Exchange. Our webinar will shift focus at 2pm ET on November 17 to explore Partners in+care and ways you can engage people living with HIV into this important work.

Introduction of Partners in+care
Thursday, November 17
2-3 pm ET
Register at this link!

In case you miss either section of the webinar, we’ll save a recorded version of the discussion on our website, enddisparitiesExchange.org.

We look forward to your participation and input!

 

^ Return to Top


HIV Training NY: Albany World AIDS Day-Save the Date! (11-4-2016)

Posted November 4, 2016

World AIDS Day – Save the date!

World AIDS Day will be held in Albany, NY at the Empire State Plaza on Tuesday, December 6th from 9am- 5pm in the convention center.

Save the date and start planning now! Schools, community groups, and individuals are invited to attend. Start the conversation in YOUR community today by sharing #WAD2016 #WORLDAIDSDAY #WADALBANY

The following will be featured:

  • Workshops (registration links below)
  • AIDS Memorial Quilt Display
  • On-Site HIV Testing
  • Exhibit Booths
  • Commissioner’s Special Recognition Awards (from 2:30-3:30 pm, recognizing individuals for their commitment, and response to improve and promote the health and well-being of all New Yorkers).

For updates click here

Learn More about Ending the Epidemic by clicking here

Workshop Registration links (all workshops held in Albany, NY, and free to attend)

Calculating Disparities in HIV Care
12/6/16
12:30- 2pm
(Convention Center Meeting Room 1):
https://hivtrainingny.org/Account/LogOn?crs=2061

NYLInks: a regional initiative improving linkage to care and retention in care for HIV+ people using a systems approach
12/6/16
9am- 11am
(Convention Center Meeting Room 2):
https://hivtrainingny.org/Account/LogOn?crs=2058

Employment and Benefits: The Value and Challenges for PLWHA
12/6/16
9am-10am
(Convention Center Meeting Room 1):
https://hivtrainingny.org/Account/LogOn?crs=2059

The Role of HIV Patient Navigators
12/6/16
10am- 11am
(Convention Center Meeting Room 1):
https://hivtrainingny.org/Account/LogOn?crs=2060

Biomedical Interventions that Save Lives! Naloxone & Buprenorphine
12/6/16
9:30am- 11:00am
(Convention Center Meeting room 3):
https://hivtrainingny.org/Account/LogOn?crs=2063

Biomedical Interventions that Save Lives! Naloxone & Buprenorphine
12/6/16
12:30am- 2:00pm
(Convention Center Meeting room 3):
https://hivtrainingny.org/Account/LogOn?crs=2064

Questions should be emailed to worldaidsday@health.ny.gov

 

^ Return to Top


AIDSinfo At-a-Glance: AIDSinfo Releases New Consumer Fact Sheets (11-4-2016)

Posted November 4, 2016

The AIDSinfo At-a-Glance News and Features can be viewed by clicking here.

Included are updates on the following:

 

^ Return to Top


NQC e-Newsletter: end+disparities Learning Exchange: Available Resources (11-4-2016)

Posted November 4, 2016

Please click here to view the e-Newsletter from the National Quality Center (NQC).

NQC is gratified at the turn out for the end + disparities Learning Exchange kick off webinar on October 20. We had over 300 individuals participate in this launch. The Health Resources and Services Administration HIV/AIDS Bureau and the National Quality Center (NQC) have teamed up to launch the end+disparities Learning Exchange, which seeks to reduce HIV-related health disparities as discussed in the National HIV/AIDS Strategy (NHAS): Updated to 2020.

The Learning Exchange is a 9-month initiative that promotes the application of quality improvement interventions with the ultimate goal of increasing viral suppression rates for disproportionately affected HIV subpopulations.

We are also pleased to bring you a profile of the St. Louis Part A program, a good example of how perseverance pays off. St. Louis has worked hard over the past few years on their quality program and in spite of staff turn over they have made impressive strides. Take a look at what the St. Louis Part A program has done in our profile article.

In This Issue

 

^ Return to Top


NYS Clinical Education: NEW CEI Courses, This Month in HIV, STD Lunch and Learn (11-1-2016)

Posted November 1, 2016

Please click here to view the latest update from the New York State Clinical Education Initiative.

Included are updates on the following:

 

^ Return to Top


NYS Medicaid Update: October (11-1-2016)

Posted November 1, 2016

Dear Medicaid Provider,

The Office of Health Insurance Programs of the New York State Department of Health has approved the release of the October 2016 Medicaid Update. Please find the full current issue as a PDF (Portable Document Format) file available to be downloaded at: http://www.health.ny.gov/health_care/medicaid/program/update/2016/oct16_mu.pdf

 

^ Return to Top


Updates from AETC Program Friends & Colleagues (10-31-2016)

Posted October 31, 2016

Updates from AETC Program Friends & Colleagues are now available by clicking here.

Included are updates on the following:

 

^ Return to Top


Updated HHS Perinatal Antiretroviral Treatment Guidelines Released (10-26-2016)

Posted October 26, 2016

The HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission announces the release of the updated Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States.

For a complete preview of key updates to the guidelines, please see What’s New in the Guidelines. Additions and revisions are also highlighted in yellow throughout the text and tables in the PDF version of the guidelines.

To view or download the guidelines, go to the Perinatal Guidelines section of AIDSinfo. Separate PDF files of the tables or recommendations can also be downloaded from the page.

 

^ Return to Top


Updates from AETC Program Friends & Colleagues (10-24-2016)

Posted October 24, 2016

Updates from AETC Program Friends & Colleagues are now available by clicking here.

Included are updates on the following:

 

^ Return to Top


AIDSinfo At-a-Glance: AIDSinfo Releases First Therapeutic HIV Vaccine Drug Record and New Consumer Materials (10-21-2016)

Posted October 21, 2016

The AIDSinfo At-a-Glance News and Features can be viewed by clicking here.

Included are updates on the following:

 

^ Return to Top


DOJ Announces the Release of Documents in Spanish Explaining the Rights of Persons with HIV/AIDS (10-19-2016)

Posted October 19, 2016

The Department of Justice has released Spanish language versions of two technical assistance publications on the rights of persons with HIV/AIDS. Both documents explain the rights of persons with HIV/AIDS under federal laws including the Americans with Disabilities Act (ADA) and how to file complaints of discrimination with appropriate federal agencies. The documents also discuss the obligations imposed on employers, businesses, and non-profit agencies that serve the public, as well as State and local governments, to avoid discriminating against persons with HIV/AIDS.

The first is a pamphlet entitled “Protecting the Rights of Persons Living with HIV/AIDS.” The second is a multi-page publication entitled “Questions and Answers: The Americans with Disabilities Act and Persons with HIV/AIDS.”

To find out more about the ADA, call the Justice Department’s toll-free ADA Information Line at 1-800-514-0301 or 1-800-514-0383 (TTY), or access its ADA.gov website.

El Departamento de Justicia anuncia la divulgación de documentos en español que explican los derechos de las personas que tienen el VIH/SIDA

El Departamento de Justicia ha emitido las versiones en español de dos publicaciones de asistencia técnica sobre los derechos de las personas que tienen el VIH/SIDA. Ambos documentos explican los derechos de las personas que tienen el VIH/SIDA conforme a las leyes federales, entre ellas, la Ley para Personas con Discapacidades (ADA, por sus siglas en inglés) y la manera de presentar denuncias de discriminación ante las entidades federales apropiadas. Además, los documentos también abordan las obligaciones que se imponen a los empleadores, los negocios y las entidades sin fines de lucro que ofrecen servicios al público, así como también a los gobiernos estatales y locales, para evitar que discriminen contra las personas que tienen el VIH/SIDA.

El primer panfleto lleva el título “En Defensa de los Derechos de las Personas con VIH/SIDA.” El segundo es una publicación de varias páginas, titulada “Preguntas y Respuestas: La Ley para Personas con Discapacidades (ADA, por sus siglas en inglés) y Personas con VIH/SIDA.”

Para obtener más información sobre la ADA, llame a la línea telefónica gratuita de Información de la ADA del Departamento de Justicia al: 800-514-0301 o 800-514-0383 (línea de teléfono de texto para las personas con problemas de audición y habla) o visite su sitio web: ADA.gov.

 

^ Return to Top


Updates from AETC Program Friends & Colleagues (10-18-2016)

Posted October 18, 2016

Updates from AETC Program Friends & Colleagues are now available by clicking here.

Included are updates on the following:

 

^ Return to Top


NYS Clinical Education: NEW CEI Courses, This Month in HIV, STD Lunch and Learn (10-18-2016)

Posted October 18, 2016

Please click here to view the latest update from the New York State Clinical Education Initiative.

Included are updates on the following:

 

^ Return to Top


NYC DOHMH Alert: New Recommendation: Conduct Routine Testing for Zika Virus through Commercial Laboratories (10-17-2016)

Posted October 17, 2016

2016 Alert #48: New Recommendation: Conduct Routine Testing for Zika Virus through Commercial Laboratories

Please share with your colleagues in Obstetrics/Gynecology, Maternal/Fetal Medicine, Internal Medicine, Family Medicine, Emergency Medicine, Urgent Care, Pediatrics, Neonatology, Infectious Disease, and Neurology:

  • Commercial laboratories now offer comprehensive diagnostic testing for Zika virus, including serology and nucleic acid amplification testing.
  • Providers caring for New York City (NYC) residents should now use commercial laboratories for routine Zika virus testing, including testing of pregnant women.
    • The NYC Health Department will host a conference call on Tuesday, October 25 at 12 pm for providers seeking additional information (details below).
  • Providers should continue to send specimens to the NYC Public Health Laboratory, and not to a commercial lab, in the following situations:
    • Infants with findings concerning for possible congenital Zika virus infections
    • Placental/fetal tissues collected at delivery or pregnancy termination (elective or spontaneous) for women with laboratory evidence of Zika virus infection during pregnancy
    • Possible Guillain-Barré syndrome or any unusual neurologic manifestation
    • Possible unusual modes of transmission (e.g., transfusion, organ transplantation)
  • The NYC Health Department will continue to provide testing for patients whose insurance does not cover the cost of testing at a commercial laboratory.

To view the entire 2016 Alert #48: New Recommendation: Conduct Routine Testing for Zika Virus through Commercial Laboratories, please click here.

 

^ Return to Top


NYC Health Advisory: Increase in Drug Overdoses Deaths Linked to Increased Presence of Fentanyl in New York City (10-17-2016)

Posted October 17, 2016

2016 Advisory #47: Increase in Drug Overdoses Deaths Linked to Increased Presence of Fentanyl in New York City

This is an update to the Health Advisory issued on April 21, 2016.

Since July 1, 2016, nearly half (47%) of confirmed drug overdose deaths involved fentanyl. In 2015, 16% of overdose deaths involved fentanyl.1 In the previous 10 years, fentanyl was relatively uncommon in overdose deaths, with fewer than 3% of deaths in New York City (NYC) involving fentanyl.

Data suggest that the increased presence of fentanyl is driving the increase in overdose fatalities. Provisional 2016 data indicate there have been 725 confirmed overdose deaths to date in NYC; 581 of these deaths occurred during the first six months of 2016. The largest increase occurred in Manhattan.

While fentanyl is most commonly found in combination with heroin-involved overdose deaths, fentanyl has also been identified in cocaine-, benzodiazepine-, and opioid analgesic-involved overdose deaths.

Fentanyl is a synthetic, short-acting opioid analgesic with a potency 50 to 100 times that of morphine. Fentanyl carries a high risk of overdose, and recent national cases of fentanyl-related morbidity and mortality increasingly have been linked to illegally manufactured fentanyl and fentanyl analogues. These drugs are sold illicitly for their heroin-like effects and may be mixed with heroin and/or cocaine with or without the user’s knowledge. In addition, recent law enforcement seizures in several jurisdictions across the United States, including New York City, have identified fentanyl sold in powder and pill formulations, which may be marked as other substances, including benzodiazepines and opioid analgesics.

The New York City Department of Health and Mental Hygiene is alerting medical personnel that: (1) a higher dose or multiple doses of naloxone per overdose event may be required to reverse some opioid-involved overdoses due to the presence of fentanyl;2,3 (2) patients presenting to emergency departments with symptoms indicating opioid intoxication may be unaware that they ingested fentanyl. Providers should be mindful that fentanyl is not detected by standard urine screens.

Clinical Information:

  • Fentanyl is an opioid analgesic. The biological effects of fentanyl are indistinguishable from those of heroin.
  • Treatment is the same as for other opioid overdose, however, larger than usual doses of naloxone (2-10mg) might be required for reversal of the opioid effects.
  • Fentanyl is not detected by standard urine opioid immunoassays; therefore, opioid exposure should not be ruled out based on toxicology screen results. Consult your laboratory for preferred testing methods.
  • Symptoms of overdose are characteristic of central nervous system depression: lethargy, respiratory depression, pinpoint pupils, change in consciousness, seizure, and/or coma.

Providers can educate patients who are substance users about overdose prevention strategies, including not to use drugs alone, test drugs before using, and recommending that patients participate in overdose prevention education at a local harm reduction program or visiting a participating NYC pharmacy to obtain naloxone for overdose reversal. There are approximately 740 participating pharmacies, including all major chains. For further information, contact DOHMH at 347-396-7909 or lmaldjian1@health.nyc.gov. A fentanyl warning poster is available to hand out or display in health care settings at: http://www1.nyc.gov/assets/doh/downloads/pdf/mental/fentanyl-poster.pdf.

Medication-assisted treatment with methadone or buprenorphine also prevents overdose. Treatment locators are available at: www.oasas.ny.gov or www.buprenorphine.samhsa.gov. Referrals for medication-assisted treatment are available at 1-800-LIFENET.

We remind medical providers that they are required to report suspect or confirmed cases of poisoning by drugs or other toxic agents within 24 hours to the Poison Control Center at 1-800-222-1222 or 212-764-7667 (POISONS). These reports are critical in detecting and preventing overdose outbreaks.

Please share this with any providers you know working with substance users in New York City.

To view the entire 2016 Advisory #47: Increase in Drug Overdoses Deaths Linked to Increased Presence of Fentanyl in New York City, please click here.

 

^ Return to Top


NQC e-Newsletter: NQC at National Ryan White Conference (10-17-2016)

Posted October 17, 2016

Please click here to view the e-Newsletter from the National Quality Center (NQC).

The National Quality Center (NQC) was proud to participate in and present at the 2016 National Ryan White Conference on HIV Care and Treatment.
Over 400 people attended our quality improvement workshops and networking sessions. We were also pleased to be able to co-present with various recipients from around the country. Visit the NQC website to access our presentations slides.

We are also pleased to announce a new initiative that focuses on ending disparities in HIV care. Check out the article below to learn how you can participate.

Also highlighted this month is the fine work of the DC EMA Collaborative; this year’s Award for Sustainable Clinical Quality Management Program winner. The work of this collaborative is a stellar example of how Ryan White HIV/AIDS Program recipients are striving to ensure the delivery of the best possible HIV care.

In This Issue

  • NQC Announcement | NQC Launches New Initiative to Reduce HIV Disparities
  • NQC Update | NQC at the National Ryan White Conference: Let’s Continue the QI Journey
  • Quality Award Profile | Award for Sustainable Clinical Quality Management Program: DC EMA Cross-Parts Collaborative
  • Quality Award Profile | Award for Leadership in Quality: Deana Hayes
  • NQC Update | Sharelab: A Community of Learners
  • NQC Update | NQC’s 2017 Trainings
  • Quality Question of the Month | How Can Recipients Better Assist Subrecipients in Quality Improvement Activities?
  • National TA Webinar | Peer Learning Session by 2016 NQC Quality Award Winners

 

^ Return to Top


AETC ShareSpot: Addiction Recovery and HIV: Finding Synergy (10-13-2016)

Posted October 13, 2016

With approximately 10% of new HIV infections occurring through shared injection equipment, and nearly 1/4 of people living with HIV (PLWH) acquiring HIV infection through injection drug use (IDU), it makes sense to include HIV prevention in the conversation about substance use. Recovery services can be utilized to directly and indirectly promote HIV and STD prevention strategies while addressing the issue of drug addiction. The Substance Abuse and Mental Health Services Administration (SAMHSA) funds peer recovery support service projects that can help HIV prevention efforts by assisting people with maintaining their recovery, and providing adherence support to PLHW. Altarum Institute’s Behavioral Health Technical Assistance Center (BHTAC) is just one program that provides consultation, technical assistance and resources to behavioral health programs, like those funded by SAMHSA. Visit ShareSpot to read “Addiction Recovery and HIV: Finding Synergy,” by Adam Viera, MPH, of BHTAC, to learn more about these projects, and how to get involved with state and community efforts to address the syndemic of HIV, viral hepatitis, overdose, and drug addiction.

 

^ Return to Top


NASTAD Announces Official Launch of His Health and Well Versed (10-12-2016)

Posted October 12, 2016

NASTAD (National Alliance of State and Territorial AIDS Directors) is excited to announce the official launch of His Health.org and Well Versed.org, two new online platforms focused on elevating the standard of healthcare for Black gay men and other men who have sex with men (MSM).

For more information, please click here.

 

^ Return to Top


NYC Health Advisory: Evaluation and Management of Infants with Possible Congenital Zika Virus Infection (10-12-2016)

Posted October 12, 2016

2016 Alert #46: Evaluation and Management of Infants with Possible Congenital Zika Virus Infection

Please share with your colleagues in Obstetrics/Gynecology, Internal Medicine, Family Medicine, Emergency Medicine, Urgent Care, Primary Care, Pediatrics, Infectious Disease, and Neurology:

  • CDC recently updated its guidance for care of infants with possible congenital Zika virus infection.
  • Key differences from past guidance include:
    • New recommendation to test infant urine and serum for Zika virus RNA.
    • Testing cord blood for Zika virus is not recommended.
    • New recommendation for postnatal head ultrasound for all infants born to mothers with laboratory evidence of Zika infection.
  • Contact the Health Department within the first 2 days of an infant’s life and before hospital discharge to discuss testing for any infant with findings consistent with congenital Zika syndrome and maternal exposure to Zika virus, regardless of maternal test results.

To view the entire 2016 Alert #46: Evaluation and Management of Infants with Possible Congenital Zika Virus Infection, please click here.

 

^ Return to Top


NQC Launches New Initiative: end+disparities Learning Exchange (10-12-2016)

Posted October 12, 2016

The National Quality Center (NQC), in collaboration with the HRSA HIV/AIDS Bureau (HAB), has created a new quality improvement initiative that seeks to work towards eliminating disparities in HIV care called the end+disparities Learning Exchange.

In July 2015, the White House released the National HIV/AIDS for the United States: Updated to 2020, emphasizing the importance of addressing disparities related to HIV. Four subpopulations were found to be exceedingly vulnerable to HIV-related inequalities:

  • MSM of Color
  • African American and Latina Women
  • Youth (aged 13 to 24 years)
  • Transgender People

The Learning Exchange is a 9-month initiative that promotes the application of quality improvement interventions with the ultimate goal of increasing viral suppression rates for these four disproportionately affected HIV subpopulations. NQC provides a series of content-rich webinars and real-world tools to assist you in your local improvement efforts.

NQC offers various opportunities for your active participation in the Learning Exchange. Our NQC Launch Announcement highlights those activities and describes them in detail.

To get involved and learn more about the Learning Exchange, please read the invitational letter from HAB and then sign up here for our upcoming kick-off webinar happening on Thursday, October 20th, at 1:00 pm EDT.

Join us and change the course of the HIV epidemic. Together, we can make a difference to end HIV disparities.

 

^ Return to Top


Updates from AETC Program Friends & Colleagues (10-10-2016)

Posted October 10, 2016

Updates from AETC Program Friends & Colleagues are now available by clicking here.

Included are updates on the following:

 

^ Return to Top


OMD Screenshot (10-10-2016)

Posted October 10, 2016

  • Track NYS’s drive to end the AIDS epidemic (EtE) by 2020 using the EtE Dashboard.
  • Abstracts are now being accepted for the New York State 2017 Clinical Conference on HIV and Hepatitis C, which will be held on May 12, 2017, in Rochester, NY. The theme of this year’s conference will be “Connecting the Pieces in Comprehensive Care.” Abstracts can be submitted here.
  • The Clinical Education Initiative (CEI) will hold a series of half-day workshops on enhancing access to PrEP among high-risk HIV-negative patients. For workshop dates and locations, visit CEI’s webpage.
  • AIDSinfo recently released new consumer factsheets on PEP, HIV/HBV, HIV/HCV, and HIV/TB.
  • Save the date: NYSDOH AIDS Institute will host a World AIDS Day celebration on December 6, 2016, at the Empire Plaza Convention Center in Albany, NY.

 

^ Return to Top


AIDSinfo At-a-Glance: Updated Consumer Fact Sheets Offer an Overview of HIV (10-7-2016)

Posted October 7, 2016

The AIDSinfo At-a-Glance News and Features can be viewed by clicking here.

Included are updates on the following:

 

^ Return to Top


HIV Training NY: World AIDS Day Commissioner's Special Recognition Awards: Call for Nominations (10-6-2016)

Posted October 6, 2016

NYSDOH is seeking nominations for this year’s Commissioner’s Special Recognition Awards

The New York State Department of Health (NYSDOH) is seeking nominations for this year’s Commissioner’s Special Recognition Awards. This email contains the link to the “Nomination Request Form.” The form can be used for an individual or team award and must be completed electronically in order to be considered for an award. The NYSDOH will be selecting up to three (3) nominees for each topic area to receive an award.

How do you make a nomination?

  • Choose one of the topic areas (check one only) listed on the Nomination Request Form.
  • In 50 words or less, summarize the activity and accomplishments of one individual or team in relation to the one topic area.
  • Include specific examples of their commitment and contributions, provide links, articles, etc. pertaining to the nominee’s accomplishments.
  • An individual or team nomination must be someone who has never received a World AIDS Day Commissioner’s Special Recognition Award.
  • Use the space provided on the Nomination Request Form for your summary.
  • Submit a completed electronic Nomination Request Form no later than November 1, 2016.

No nominations will be accepted after 5:00pm on November 1, 2016

The nominator will be notified by the NYSDOH AIDS Institute if their nominee has been selected to receive an award.

Please submit your Nomination Request Form on time! Click the link below to access the form.

Nomination Request Form

Questions should be emailed to worldaidsday@health.ny.gov

 

^ Return to Top


NYC Health: Help Stop the Opioid Epidemic (10-5-2016)

Posted October 5, 2016

Dear Colleague:

An opioid epidemic is affecting communities and families all across the United States, and New York City (NYC) hasn’t been spared. According to 2015 provisional data, there were 937 unintentional overdose deaths in NYC and 80% involved an opioid.

Ensure your patients’ safety by prescribing judiciously. If opioids are warranted for acute pain, prescribe only short-acting agents for a limited duration. A 3-day supply is usually sufficient. Avoid prescribing opioids for chronic noncancer pain unless other approaches have been ineffective (see Preventing Misuse of Prescription Opioid Drugs). Learn to recognize opioid use disorder and recommend effective treatment, including buprenorphine (see Buprenorphine—an Office-based Treatment for Opioid Use Disorder). For information on free buprenorphine physician waiver trainings and technical assistance, please e-mail buprenorphine@health.nyc.gov.

First Lady Chirlane McCray has made mental health, including substance misuse, a priority for this administration through ThriveNYC and is proud to support US Surgeon General Dr Vivek H. Murthy’s effort to turn the tide on the nation’s prescription opioid epidemic. We encourage you to visit http://www.turnthetiderx.org/join to learn more about Dr Murthy’s efforts and what you can do to help.

Thank you for your continued commitment to improving the health of all New Yorkers.

 

^ Return to Top


NYC Health Department Releases Report on Hepatitis Surveillance and Programs in NYC (10-5-2016)

Posted October 5, 2016

Health Department Releases Report On Hepatitis Surveillance And Programs In New York City, Launches Ad Campaign To Promote New Health Care Services For People Living With Viral Hepatitis

More than 15,000 people were newly reported with hepatitis B or C in 2015

NYC Council invests $1.5 million in Hepatitis Community Health Programs in FY2017

New ad campaign encourages New Yorkers to get tested and connect to care

October 4, 2016 – The Health Department today released a new report detailing the City’s hepatitis B and C surveillance, research, and programs in 2015. The latest data show a continued decrease (4.7 percent) in the rate of chronic hepatitis C cases compared to the previous year, and a slight uptick (3.5 percent) in chronic hepatitis B cases in 2015. To raise awareness about hepatitis C care and treatment programs throughout the city, the Health Department is launching a new media campaign this week to encourage New Yorkers to get tested for hepatitis C and, if positive, to get into care to treat and cure the infection. The targeted print campaign will focus on areas of Brooklyn with the highest numbers of hepatitis C cases in NYC, including Bedford-Stuyvesant, Crown Heights, Williamsburg, East New York, and Flatbush. The eight-week awareness campaign will run in English and Spanish and be featured on bus shelters, laundromats, barbershops, and salons. The print ads will be accompanied with social media ads targeting New Yorkers over the age of 50 in the 20 citywide ZIP codes with the highest number of newly reported hepatitis C cases in 2015.

To read more, please click here.

 

^ Return to Top


FDA Hepatitis Update: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C (10-4-2016)

Posted October 4, 2016

FDA is warning about the risk of hepatitis B virus (HBV) becoming an active infection again in any patient who has a current or previous infection with HBV and is treated with certain direct-acting antiviral (DAA) medicines for hepatitis C virus. In a few cases, HBV reactivation in patients treated with DAA medicines resulted in serious liver problems or death.

As a result, we are requiring a Boxed Warning, our most prominent warning, about the risk of HBV reactivation to be added to the drug labels of these DAAs directing health care professionals to screen and monitor for HBV in all patients receiving DAA treatment. This warning will also be included in the patient information leaflet or Medication Guides for these medicines.

Direct-acting antiviral medicines are used to treat chronic hepatitis C virus (HCV) infection, an infection that can last a lifetime. These medicines reduce the amount of HCV in the body by preventing HCV from multiplying, and in most cases, they cure HCV. Without treatment, HCV can lead to serious liver problems including cirrhosis, liver cancer, and death (see List of Direct-Acting Antivirals).

Patients should tell your health care professional if you have a history of hepatitis B infection or other liver problems before being treated for hepatitis C. Do not stop taking your DAA medicine without first talking to your health care professional. Stopping treatment early could result in your virus becoming less responsive to certain hepatitis C medicines. Read the patient information leaflet or Medication Guide that comes with each new prescription because the information may have changed. Contact your health care professional immediately if you develop fatigue, weakness, loss of appetite, nausea and vomiting, yellow eyes or skin, or light-colored stools, as these may be signs of serious liver problems.

We identified 24 cases of HBV reactivation reported to FDA1 and from the published literature in HCV/HBV co-infected patients treated with DAAs during the 31 months from November 22, 2013 to July 18, 2016.2-7 This number includes only cases submitted to FDA, so there are likely additional cases about which we are unaware. Of the cases reported, two patients died and one required a liver transplant. HBV reactivation was not reported as an adverse event in the clinical trials submitted for the DAA approvals because patients with HBV co-infection were excluded from the trials. The trials excluded these patients in order to specifically evaluate the safety of DAAs, including their effects on the liver, in patients infected with only HCV and without the presence of another virus which affects the liver (see Data Summary).

We urge health care professionals and patients to report side effects involving DAAs and other medicines to the FDA MedWatch program, using the information in the “Contact FDA” box at the bottom of the page.

New Guidance: Test for HBV Before Starting DAAs for HCV
It is important that all patients beginning hepatitis C (HCV) treatment using direct acting antiviral (DAA) therapies should be assessed for hepatitis B (HBV), according to the AASLD/Infectious Diseases Society of America (IDSA) Guidance Panel. The AASLD/IDSA Recommendations for Testing, Managing and Treating Hepatitis C have been updated to include this new practice guidance.

In addition to testing, the Guidance Panel recommends:

  • HBV vaccination for all susceptible individuals.
  • Obtaining a test for HBV DNA prior to DAA therapy in patients who could be actively replicating.
  • Starting patients who meet criteria for treatment of active HBV infection on therapy at the same time — or before — HCV DAA therapy is started.
  • Monitoring patients with low or undetectable HBV DNA levels at regular intervals as recommended by the AASLD’s HBV treatment guidelines.

Visit HCVguidelines.org for more information about the newest recommendations and to view the full report and to read the entire FDA Safety Communication on hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C.

 

^ Return to Top


Updates from AETC Program Friends & Colleagues (10-3-2016)

Posted October 3, 2016

Updates from AETC Program Friends & Colleagues are now available by clicking here.

Included are updates on the following:

 

^ Return to Top


NYS Clinical Education: NEW CEI Courses, This Month in HIV, STD Lunch and Learn (10-3-2016)

Posted October 3, 2016

Please click here to view the latest update from the New York State Clinical Education Initiative.

Included are updates on the following:

 

^ Return to Top


NYS Medicaid Update: September (9-29-2016)

Posted September 29, 2016

Dear Medicaid Provider,

The Office of Health Insurance Programs of the New York State Department of Health has approved the release of the September 2016 Medicaid Update. Please find the full current issue as a PDF (Portable Document Format) file available to be downloaded at: http://www.health.ny.gov/health_care/medicaid/program/update/2016/sep16_mu.pdf

 

^ Return to Top


FDA HIV Update: Comment Request Regarding Proposed Agency Information Collection Activities (9-29-2016)

Posted September 29, 2016

Comment Request Regarding Proposed Agency Information Collection Activities Regarding Risk Factor Elicitation for the Transfusion-Transmissible Infection Monitoring System

In today’s Federal Register, FDA is announcing an opportunity for public comment on the proposed collection of certain information by the Agency, under the Paperwork Reduction Act of 1995. The notice is required to seek Office of Management and Budget approval to conduct a survey intended to assess risk factors associated with transfusion-transmissible infections (TTI) in blood donors. The survey will be conducted under the Transfusion-Transmissible Infections Monitoring System program, and will also include interviews/epidemiologic surveys of donors with donations testing positive for a TTI, as well as donors with donations testing negative as controls. Monitoring behavioral risk factors for viral infections in both infected and uninfected donors is particularly important at this time because of the recent change in the deferral policy for men who have sex with men (MSM).

The current survey will help identify the specific risk factors for HIV and the prevalence of the risk factors in blood donors. This will help inform FDA on the proportion of new infections among all HIV positive blood donors. Donations from individuals recently infected with HIV have the greatest potential transmission risk because on rare occasions they could be missed during routine blood testing. The TTIMS study will enable a correlation of the positive test results with the risk interview survey data, so the probable reasons for infection can be determined. The study will help the FDA evaluate the effectiveness of screening strategies in reducing the risk of HIV transmission from donors with risk factors, and to evaluate if there are unexpected consequences associated with the recent change in the donor deferral policy such as an increase in HIV incidence among donors.

The results from the survey will inform the FDA regarding future blood donor deferral policy options to reduce the risk of HIV transmission, including the feasibility of moving from the existing time-based deferrals related to risk behaviors to alternate deferral options, such as the use of individual risk assessments. The information will also help with the design of potential studies to evaluate the feasibility and effectiveness of such alternative deferral options.

This is a separate action, and should not be confused with the opening of the public docket in July 2016, which requested comments supported by scientific evidence regarding potential blood donor deferral policy options to reduce the risk of HIV transmission by blood and blood products. However, both actions are part of the agency’s ongoing activities to assess the safety of the blood supply and to help evaluate its blood donor deferral policies.

Comments may be submitted in either written or electronic form in accordance with the instructions provided in the notice.

For more information, please click here.

 

^ Return to Top


Updates from AETC Program Friends & Colleagues (9-26-2016)

Posted September 26, 2016

Updates from AETC Program Friends & Colleagues are now available by clicking here.

Included are updates on the following:

 

^ Return to Top


HIV Training NY: New Training Calendar Available on HIVtrainingny.org (Fall 2016 & Winter 2017) (9-23-2016)

Posted September 23, 2016

New Training Calendar Now Available

The AIDS Institute is excited to announce the arrival of our fall and winter training calendar. We have scheduled over 100 courses across New York State. These courses take place between October ’16 and March ’17. Among them are familiar courses as well as many different new course offerings.

We continue to offer face to face trainings in different areas, live webinars, and online trainings for you to take at your own pace!

Our newest online courses below give you opportunities have a short, interactive exploration across different topics.

Title: Engagement in Care Series: Older HIV+ Men who are Gay or MSM

This series addresses the case of Will, a 51 year old gay man who has been living with HIV for thirty years. By the end of the module, you will be able to:

  • Describe the importance of engaging older HIV+ men who are gay or MSM in care;
  • List barriers to linkage and retention that older HIV+ men who are gay or MSM face;
  • Describe strategies that health and human services providers can use to improve linkage and retention among older HIV+ men who are gay or MSM.

Register for this training here:
https://hivtrainingny.org/Account/LogOn?crs=1886

Title: Online Learning:Peer Worker Code of Ethics in Practice

This 30-minute online module will provide Peer Workers with an opportunity to reflect on situations they may encounter in their work and consider how the Peer Worker Code of Ethics can help to determine the best course of action.

Register for this training here:
https://hivtrainingny.org/Account/LogOn?crs=1907

Title: Online Learning: Motivational Interviewing Overview

This 30-minute on-line module will provide health and human service providers with an introduction to Motivational Interviewing. The course will review the basic elements of Motivational Interviewing and how it can be helpful to providers when working with clients who are HIV positive, infected with Hepatitis C, or require harm reduction services.

Register for this training here:
https://hivtrainingny.org/Account/LogOn?crs=1906

This is just a small snap shot of all of the courses we have available. Please visit our website, www.hivtrainingny.org and click on the “courses” tab to view any and all of the trainings we have. Some of our courses have OASAS certification, as well as offer CNE credits.

Please call us with any questions and we are happy to help. A member of the Education and Training team can be reached at (518) 474-3045 or HIVET@health.ny.gov

____________________________________

To register for any course, click on the appropriate registration link and enter your account log-in information.If you do not have an account with hivtrainingny.org, you will need to sign up for one prior to registering for a course. For help in registering, please contact the NYSDOH AIDS Institute’s HIV Education and Training Program at (518) 474-3045.

 

^ Return to Top


AIDSinfo At-a-Glance: New Consumer Fact Sheets and New Infographic (9-23-2016)

Posted September 23, 2016

The AIDSinfo At-a-Glance News and Features can be viewed by clicking here.

Included are updates on the following:

 

^ Return to Top


OMD Screenshot (9-21-2016)

Posted September 21, 2016

  • The NYSDOH AIDS Institute released data briefs reporting the reasons behind disengagement in care among PLWH in NYS. Region-specific reports can be found on the NY Links website.
  • New findings published in a recent issue of the JIAPAC explore the determinants of racial and ethnic disparities in viral load suppression in NYS.
  • The Clinical Education Initiative is launching a new “telementoring” program, Project ECHO, for providers of STD clinical care that connects experts to clinicians in local practice settings. To learn more about participating, visit Project ECHO’s webpage.
  • eHEPQUAL, a new web-based surveillance platform, was recently launched in NYS to track the quality of HCV care. An overview can be found here.

 

^ Return to Top


HIV Training NY: Understanding and Making Referrals for Substance Use Treatment in NYS (9-21-2016)

Posted September 21, 2016

Have you ever experienced difficulty getting a client into substance use treatment?

Learn now to help your clients access the care and services they need.

The AIDS Institute is partnering with the NYS Office of Alcoholism and Substance Abuse Services (OASAS) to offer a regional sessions entitled: “Understanding and Making Referrals for Substance Use Treatment in NYS.” Each three hour session will share information with community providers about the full range of substance use treatment services available through OASAS. Emphasis will be placed on new developments in recovery oriented treatment, regional partnership building and how to make effective referrals for these services.

By the end of the session, participants will be able to:

  1. Describe the full range of recovery oriented treatment services available through OASAS;
  2. Make referrals for the range of treatment options, including addressing reimbursement/ insurance coverage issues;
  3. Recall information about the important role of Peer Recovery Advocates;
  4. Identify regional issues and build partnerships;
  5. Learn about OASAS resources, videos, websites, etc.

This training will be held across New York State on the following dates and times:

October 21st | New York City | Click here to register

October 26th | Syracuse | Click here to register

November 9th | Long Island | Click here to register

November 10th | New York City | Click here to register

November 14th| Buffalo | Click here to register

November 15th | Rochester | Click here to register

November 29th | Albany | Click here to register

____________________________________
To register for any course, click on the appropriate registration link and enter your account log-in information.If you do not have an account with hivtrainingny.org, you will need to sign up for one prior to registering for a course. For help in registering, please contact the NYSDOH AIDS Institute’s HIV Education and Training Program at (518) 474-3045.

 

^ Return to Top


CDC Health Update: CDC Updates Guidance for Travel and Testing of Pregnant Women and Women of Reproductive Age for Zika Virus Infection (9-20-2016)

Posted September 20, 2016

CDC Updates Guidance for Travel and Testing of Pregnant Women and Women of Reproductive Age for Zika Virus Infection Related to the Ongoing Investigation of Local Mosquito-borne Zika Virus Transmission in Miami-Dade County, Florida

There continues to be local mosquito-borne Zika virus transmission in areas of Miami-Dade County, Florida. Clinicians should ask their patients about a history of being in Miami-Dade County on or after June 15, 2016 or in other areas with active Zika virus transmission (for the full list, see: http://www.cdc.gov/zika/geo/active-countries.html). All patients who were in Miami-Dade County while pregnant on or after June 15, 2016 or in other areas with active Zika virus transmission are eligible for testing via DOHMH. Providers can call 1-866-692-3641 to arrange testing through DOHMH.

To view the full health advisory, please click here.

 

^ Return to Top


AETC Program Quarterly Newsletter – Fall 2016 (9-20-2016)

Posted September 20, 2016

The AETC Program Quarterly Newsletter – Fall Edition is now available. It can be viewed here, or accessed via the AETC National Coordinating Resource Center website here.

 

^ Return to Top


NYS Clinical Education: New Courses, PrEP Workshop, HIV Intensive Training Preceptorship, STD Intensive Course, ECHO Clinic (9-20-2016)

Posted September 20, 2016

Please click here to view the latest update from the New York State Clinical Education Initiative.

Included are updates on the following:

 

^ Return to Top


FDA HIV Update: Important Labeling Update (9-19-2016)

Posted September 19, 2016

The Food and Drug Administration is announcing that the following HIV drug labels have been updated to include Latuda (lurasidone), an antipsychotic used to treat adult patients with depressive episodes in bipolar I disorder (bipolar depression), and schizophrenia, in adults. Lurasidone was added to Section 4 of the label, Contraindications, due to the potential for serious and/or life-threatening reactions to the following product labels:

Aptivus (tipranavir)

Crixivan (indinavir)

Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide)

Invirase (saquinavir)

Kaletra (lopinavir/ritonavir)

Lexiva (fosamprenavir) note: lurasidone is contraindicated due to the potential for serious and/or life-threatening reactions if Lexiva is coadministered with ritonavir.

Norvir (ritonavir)

Prezista (darunavir)

Reyataz (atazanavir) – note: lurasidone is contraindicated due to the potential for serious and/or life-threatening reactions if Reyataz is coadministered with ritonavir.

Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate)

Viracept (nelfinavir)

Of note, Evotaz (atazanavir/cobicistat) and Prezcobix (darunavir/cobicistat) labels already include lurasidone as a contraindicated medication in section 4.

For more information, please click here.

 

^ Return to Top


Updates from AETC Program Friends & Colleagues (9-19-2016)

Posted September 19, 2016

Updates from AETC Program Friends & Colleagues are now available by clicking here.

Included are updates on the following:

 

^ Return to Top


FDA launches competition to spur innovative technologies to help reduce opioid overdose deaths (9-19-2016)

Posted September 19, 2016

Contest seeks to stimulate development of a mobile app to connect those experiencing an overdose with the potentially life-saving antidote

The U.S. Food and Drug Administration today announced the 2016 Naloxone App Competition, a public contest focused on developing innovative technologies to combat the rising epidemic of opioid overdose.

Read more.

 

^ Return to Top


CDC Vaccine Recommendations for 2016-2017 Influenza Season: Medscape Commentary (9-19-2016)

Posted September 19, 2016

CDC Vaccine Recommendations for 2016-2017 Influenza Season: Medscape Commentary

 

^ Return to Top


OMD Screenshot: New York State Association for Rural Health Conference (9-16-2016)

Posted September 16, 2016

The New York State Association for Rural Health is holding its annual conference on September 22-23, 2016, in Clayton, NY. The theme of this year’s conference is “Navigating the Waters of Change.” Registration remains open and can be accessed here. The conference program, which features speakers, panels, and networking opportunities, can be found here.

 

^ Return to Top


Updates from AETC Program Friends & Colleagues (9-12-2016)

Posted September 12, 2016

Updates from AETC Program Friends & Colleagues are now available by clicking here.

Included are updates on the following:

 

^ Return to Top


AIDSinfo At-a-Glance: Scientific/Clinical and Community Member Nominations Now Being Accepted for the HHS Guidelines Panels (9-9-2016)

Posted September 9, 2016

The AIDSinfo At-a-Glance News and Features can be viewed by clicking here.

Included are updates on the following:

 

^ Return to Top


NQC e-Newsletter: Quality Award Winners Profiled (9-9-2016)

Posted September 9, 2016

Please click here to view the e-Newsletter from the National Quality Center (NQC).

This month we are pleased to profile two of our 2016 NQC Quality of Care Awards winners. Their work stood out and are outstanding examples of local quality improvement champions. Congratulations to this year’s winners. Next month we will profile more NQC Quality of Care Award winners. In the near future, they will be presenting on an NQC National TA Webinar to let others know about the exemplary work.

We are pleased to have provided many offerings at the recent 2016 Ryan White Conference on HIV Care and Treatment. Take a look at our recap in this issue.

In This Issue

  • NQC Update | Quality Award Profile
  • NQC Update | Quality Award Profile
  • NQC Update | TCQPlus
  • NQC Update | Reflections from 2016 National Ryan White Conference
  • Quality Question of the Month: | Do You Actively Engage Consumers in your Local Improvement Effort
  • National TA Webinar | Lean and You
  • NQC Job Forum | New Listing This Month

 

^ Return to Top


FDA Approved Changes to the SUSTIVA Label (9-7-2016)

Posted September 7, 2016

FDA recently approved changes to the SUSTIVA (efavirenz) product labeling to include a new Warnings and Precautions regarding QTc prolongation.

Click here to view the main changes to the product labeling.

 

^ Return to Top


FDA Approved Changes to the GENVOYA (9-7-2016)

Posted September 7, 2016

Recently, FDA approved changes to the GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide), 150/150/200/10 mg fixed-dose combination tablet product labeling.

Click here to view the main updates.

 

^ Return to Top


NYC Health Advisory: Increasing Antimicrobial Resistance of Shigella among MSM in NYC (9-6-2016)

Posted September 6, 2016

2016 Alert #41: Increasing Antimicrobial Resistance of Shigella among Men Who Have Sex with Men in NYC

  • Shigella infections with decreased susceptibility to azithromycin are increasing among men who have sex with men (MSM) in NYC.
  • Only certain individuals at high risk for invasive disease should receive antibiotics. Clinicians should not prescribe antibiotics to patients with Shigella infection unless absolutely necessary.
  • Ampicillin and trimethoprim-sulfamethoxazole should not be used as empiric treatment for Shigella infections in NYC. Antimicrobial susceptibility results should guide treatment.

To view the entire 2016 Alert #41: Increasing Antimicrobial Resistance of Shigella among Men Who Have Sex with Men in NYC, please click here.

 

^ Return to Top


NYS Clinical Education: New Courses, STD LL, STD-HIV, PrEP Implementation Workshop, HIV HepC, STD Intensive Course (9-6-2016)

Posted September 6, 2016

Please click here to view the latest update from the New York State Clinical Education Initiative.

Included are updates on the following:

 

^ Return to Top


NYS Medicaid Update: August (9-1-2016)

Posted September 1, 2016

Dear Medicaid Provider,

The Office of Health Insurance Programs of the New York State Department of Health recently got a new look and main page for the Medicaid Update. It can be viewed along with the newly approved August 2016 Medicaid Update and can better accommodate smaller devices.

Please find the full current issue as a PDF (Portable Document Format) file available to be downloaded at: http://www.health.ny.gov/health_care/medicaid/program/update/2016/aug16_mu.pdf

 

^ Return to Top


WHO Releases New Treatment Guidelines for Chlamydia, Gonorrhoea and Syphilis (8-30-2016)

Posted August 30, 2016

Growing antibiotic resistance forces updates to recommended treatment for sexually transmitted infections

WHO releases new treatment guidelines for chlamydia, gonorrhoea and syphilis

30 AUGUST 2016 | GENEVA – New guidelines for the treatment of three common sexually transmitted infections (STIs) have been issued by the World Health Organization (WHO) in response to the growing threat of antibiotic resistance.

To read the complete news release, please click here.

 

^ Return to Top


Healthcare Stories Project Activity 3 Materials (8-26-2016)

Posted August 26, 2016

Materials for the Healthcare Stories Project Activity 3 are now available.

Activity 3 Materials:

For more information, please click here.

 

^ Return to Top


NQC Special Announcement: Wrap up of NQC at the 2016 National Ryan White Conference on Care and Treatment (8-26-2016)

Posted August 26, 2016

On behalf of the entire NQC staff we wanted to extend our thanks to all of you who attended the NQC workshops at the 2016 National Ryan White Conference for HIV Care and Treatment in Washington, DC.

Download our Presentation Slides
For those who could not attend our sessions or want to share with others, all our presentation slides are now posted to the NQC website for immediate download by clicking here.

Take advantage!

Access the Pictures We Took at The Conference
We took many pictures at our workshops. You can review them by visiting our website by clicking here.

Find yourself!

It Was a Busy Conference for Us

    - NQC hosted 8 NQC workshops and network sessions
    - Over 400 individuals attended these NQC offerings
    - Our exhibit booth handed out over 2,000 NQC guides and QI publications

Thanks to all who made this conference so successful.

Need to find NQC after the conference?

It’s easy!

Mail
National Quality Center
New York State Department of Health
AIDS Institute
90 Church Street, 13th floor
New York, NY 10007-2919
Phone
212.417.4730
Website
NationalQualityCenter.org
Email
Info@NationalQualityCenter.org

 

^ Return to Top


FDA Advises Testing for Zika Virus in All Donated Blood and Blood Components in the US (8-26-2016)

Posted August 26, 2016

FDA advises testing for Zika virus in all donated blood and blood components in the US

As a further safety measure against the emerging Zika virus outbreak, today the U.S. Food and Drug Administration issued a revised guidance recommending universal testing of donated Whole Blood and blood components for Zika virus in the U.S. and its territories.

 

^ Return to Top


AIDSinfo: At-a-Glance: Updates to the Cryptococcosis Section of the Adult and Adolescent Opportunistic Infections Guidelines (8-26-2016)

Posted August 26, 2016

The AIDSinfo At-a-Glance News and Features can be viewed by clicking here.

Included are updates on the following:

 

^ Return to Top


NYC Health Advisory: New Zika Virus Testing Policy in New York City (8-24-2016)

Posted August 24, 2016

2016 DOHMH Advisory #37: New Zika Virus Testing Policy in New York City

Please share with your colleagues in Obstetrics/Gynecology, Internal Medicine, Family Medicine, Emergency Medicine, Urgent Care, Pediatrics, Infectious Disease, and Neurology:

  • An increasing number of commercial clinical laboratories now offer testing for Zika virus infection.
  • If Zika virus testing is clinically indicated, providers should use commercial clinical laboratories for:
    • Non-pregnant persons with a history of travel to an area with active Zika virus transmission*
  • If Zika virus testing is clinically indicated, providers should use the Health Department for:
    • Pregnant women
    • Infants
    • Persons with Guillain-Barré syndrome or other neurological complications
    • Suspected cases of sexual transmission
    • Suspected cases of local mosquito-borne transmission
  • The Health Department will continue to provide testing if the provider cannot use a commercial clinical laboratory or the patient is uninsured.

To view the entire 2016 DOHMH Advisory #37: New Zika Virus Testing Policy in New York City, please click here.

 

^ Return to Top


NYS Clinical Education: STD Lunch and Learn, STD-HIV Inter-relationship, PrEP Implementation Workshop (8-23-2016)

Posted August 9, 2016

Please click here to view the latest update from the New York State Clinical Education Initiative.

Included are updates on the following:

 

^ Return to Top


Updates from AETC Program Friends & Colleagues (8-22-2016)

Posted August 22, 2016

Updates from AETC Program Friends & Colleagues are now available by clicking here.

Included are updates on the following:

 

^ Return to Top


NQC e-Newsletter: NQC Award Winners Are Announced (8-16-2016)

Posted August 16, 2016

Please click here to view the e-Newsletter from the National Quality Center (NQC).

 

^ Return to Top


NQC Activities and Locations: 2016 National Ryan White Conference (8-19-2016)

Posted August 19, 2016

Please click here to view the roster of National Quality Center (NQC) workshops.

 

^ Return to Top


HIV Training NY: "Could it be Early HIV?" Materials Now Available! (8-15-2016)

Posted August 15, 2016

“Could it be Early HIV?” Brochure now available in English, Spanish coming soon!

On behalf of the AIDS Institute Consumer Materials Initiative, we are pleased to announce a brochure entitled, “Could it be Early HIV?” Early HIV, also referred to as acute HIV, is the first stage of HIV Infection and the time when HIV is the most easily passed to others. It is important to identify HIV as early as possible to promote and improve individual health outcomes. The earlier an individual is diagnosed, the quicker they are able to access treatment to improve health outcomes and take steps to prevent passing the virus to others. The material also provides information and links to New York State Department of Health (NYSDOH) resources related to Early HIV. This is just one more way important way to End the Epidemic!

This brochure is available in English with the Spanish version coming soon.

http://www.health.ny.gov/publications/9585.pdf

* English: Brochure – Publication/Inventory #9585 – available
* Spanish: Brochure – Publication/Inventory #9586 – not yet available

The PDF of this brochure can be accessed by clicking here.

Educational materials are also available on a number of other topics related to HIV, STDs and viral hepatitis. To access the comprehensive materials order form, please visit our website by clicking here.

The NYSDOH Distribution Center is now open at its new location. If you would like to order materials, please use the on-line order form or send an e-mail to: b0019w@health.ny.gov and indicate the publication/inventory number noted above and the quantity of materials (25, 50 or 100) you would like.

 

^ Return to Top


Updates from AETC Program Friends & Colleagues (8-15-2016)

Posted August 8, 2016

Updates from AETC Program Friends & Colleagues are now available by clicking here.

Included are updates on the following:

 

^ Return to Top


AIDSinfo: At-a-Glance: Scientific/Clinical Member Nominations Now Being Accepted (8-12-2016)

Posted August 12, 2016

The AIDSinfo At-a-Glance News and Features can be viewed by clicking here.

Included are updates on the following:

 

^ Return to Top


NYC Health: Gonorrhea with Reduced Susceptibility to Azithromycin Increasing in NYC (8-9-2016)

Posted August 9, 2016

2016 Health Alert #32 Gonorrhea with Reduced Susceptibility to Azithromycin Increasing in New York City

  • Azithromycin is becoming less effective at killing Neisseria gonorrhoeae.
  • Treat gonorrhea with Ceftriaxone 250mg intramuscularly PLUS azithromycin 1g orally. Do not treat with only one antimicrobial.
  • For patients with persistent symptoms, perform nucleic acid amplification testing and culture that includes ceftriaxone and azithromycin antibiotic susceptibility testing.
  • Call 866-692-3641 to notify the Health Department of suspected treatment failures.

To view the entire 2016 Health Alert #32 Gonorrhea with Reduced Susceptibility to Azithromycin Increasing in New York City, please click here.

 

^ Return to Top


NYS Clinical Education: New Courses, CEI Line Update, Syphilis Series, Ending The HIV And STI Epidemic (8-9-2016)

Posted August 9, 2016

Please click here to view the latest update from the New York State Clinical Education Initiative.

Included are updates on the following:

 

^ Return to Top


Updates from AETC Program Friends & Colleagues (8-8-2016)

Posted August 8, 2016

Updates from AETC Program Friends & Colleagues are now available by clicking here.

Included are updates on the following:

 

^ Return to Top


CDC Health Advisory: Guidance on Travel and Testing of Pregnant Women and Women of Reproductive Age for Zika Virus Infection (8-1-2016)

Posted August 1, 2016

This is an official
CDC HEALTH ADVISORY

Distributed via the CDC Health Alert Network
August 1, 2016, 1300 ET (1:00 PM ET)
CDCHAN-00393

CDC Guidance for Travel and Testing of Pregnant Women and Women of Reproductive Age for Zika Virus Infection Related to the Investigation for Local Mosquito-borne Zika Virus Transmission in Miami-Dade and Broward Counties, Florida

Summary
The Florida Department of Health (FL DOH) has identified an area with local mosquito-borne Zika virus transmission (active Zika virus transmission) in Miami (http://www.cdc.gov/zika/intheus/florida-update.html). Based on the earliest time of symptom onset and a maximal two-week incubation period for Zika virus, this guidance applies to women of reproductive age and their partners who live in or traveled to this area after June 15, 2016.

This is an ongoing investigation, and CDC is rapidly learning more about the extent of active Zika virus transmission in the area identified by the FL DOH. With the recommendations below, CDC is applying existing guidance to the occurrence of Zika virus transmission in this area of Florida. As more information becomes available, we will update these recommendations.

Recommendations

  1. Pregnant women should avoid non-essential travel to the area with active Zika virus transmission identified by the FL DOH.
  2. Pregnant women and their partners living in or traveling to the area with active Zika virus transmission identified by the FL DOH should follow steps to prevent mosquito bites (http://www.cdc.gov/zika/prevention/prevent-mosquito-bites.html).
  3. Women and men who live in or who have traveled to the area with active Zika virus transmission identified by the FL DOH and who have a pregnant sex partner should consistently and correctly use condoms or other barriers to prevent infection during sex or not have sex for the duration of the pregnancy.
  4. All pregnant women in the United States should be assessed for possible Zika virus exposure during each prenatal care visit. Women with ongoing risk of possible exposure include those who live in or frequently travel to the area with active Zika virus transmission identified by the FL DOH. Women with limited risk include those who traveled to the area with active Zika virus transmission identified by the FL DOH or had sex with a partner who lives in or traveled to the area with active Zika virus transmission without using condoms or other barrier methods to prevent infection. Each evaluation should include an assessment of signs and symptoms of Zika virus disease (acute onset of fever, rash, arthralgia, conjunctivitis), their travel history as well as their sexual partner’s potential exposure to Zika virus and history of any illness consistent with Zika virus disease to determine whether Zika virus testing is indicated.
  5. Pregnant women with possible exposure to Zika virus and signs or symptoms consistent with Zika virus disease should be tested for Zika virus infection based on time of evaluation relative to symptom onset in accordance with CDC guidance (http://www.cdc.gov/mmwr/volumes/65/wr/mm6529e1.htm?s_cid=mm6529e1_e).
  6. Pregnant women with ongoing risk of possible Zika virus exposure and who do not report symptoms of Zika virus disease should be tested in the first and second trimester of pregnancy in accordance with CDC guidance (http://www.cdc.gov/mmwr/volumes/65/wr/mm6529e1.htm?s_cid=mm6529e1_e).
  7. Pregnant women with limited risk and who do not report symptoms should consult with their healthcare providers to obtain testing for Zika virus infection based on the elapsed interval since their last possible exposure in accordance with CDC guidance (http://www.cdc.gov/mmwr/volumes/65/wr/mm6529e1.htm?s_cid=mm6529e1_e).
  8. Women with Zika virus disease should wait at least eight weeks and men with Zika virus disease should wait at least six months after symptom onset to attempt conception.
  9. Women and men with ongoing risk of possible Zika virus exposure who do not have signs or symptoms consistent with Zika virus disease and are considering pregnancy should consult their healthcare provider. Due to the ongoing risk of possible Zika virus exposure, healthcare providers should discuss the risks of Zika, emphasize ways to prevent Zika virus infection, and provide information about safe and effective contraceptive methods. As part of their pregnancy planning and counseling with their health care providers, some women and their partners living in the area with active Zika virus transmission identified by the FL DOH might decide to delay pregnancy.
  10. Women and men with limited risk and who do not report signs or symptoms consistent with Zika virus disease should wait at least eight weeks after last possible exposure to attempt conception.

Background
Zika is spread to people primarily through the bite of an infected Aedes species mosquito (Ae. aegypti and Ae. albopictus). Zika virus can also be sexually transmitted. Zika virus infection during pregnancy can cause microcephaly and severe fetal brain defects, and has been associated with other adverse pregnancy outcomes. Most persons infected with Zika virus will not have symptoms; infants with microcephaly and other birth defects have been born to women with Zika virus infection who do not report symptoms.

CDC’s testing recommendations for pregnant women with ongoing or limited risk for possible Zika virus exposure who report clinical illness consistent with Zika virus disease (symptomatic pregnant women) are the same. Symptomatic pregnant women who are evaluated less than two weeks after symptom onset should receive serum and urine Zika virus rRT-PCR testing. Symptomatic pregnant women who are evaluated two to 12 weeks after symptom onset should first receive a Zika virus immunoglobulin (IgM) antibody test; if the IgM antibody test result is positive or equivocal (unclear), serum and urine rRT-PCR testing should be performed.

Testing recommendations for pregnant women with possible Zika virus exposure who do not report clinical illness consistent with Zika virus disease (asymptomatic pregnant women) differ based on the circumstances of possible exposure. For asymptomatic pregnant women with ongoing risk for possible exposure and who are evaluated less than two weeks after last possible exposure, rRT-PCR testing should be performed. If the rRT-PCR result is negative, a Zika virus IgM antibody test should be performed two to 12 weeks after the exposure. Asymptomatic pregnant with limited risk for possible exposure who are first evaluated 2–12 weeks after their last possible exposure should first receive a Zika virus IgM antibody test; if the IgM antibody test result is positive or equivocal, serum and urine rRT-PCR should be performed. Asymptomatic pregnant women with ongoing risk for possible exposure to Zika virus should receive Zika virus IgM antibody testing as part of routine obstetric care d uring the first and second trimesters; immediate rRT-PCR testing should be performed when IgM antibody test results are positive or equivocal.

Further information on the interpretation of testing results and clinical management of pregnant women with laboratory evidence of possible Zika virus infection are available below.

For more information:

The Centers for Disease Control and Prevention (CDC) protects people’s health and safety by preventing and controlling diseases and injuries; enhances health decisions by providing credible information on critical health issues; and promotes healthy living through strong partnerships with local, national, and international organizations.

 

^ Return to Top


Promoting PrEP in NYS (8-1-2016)

Posted August 1, 2016

New York State is leading the way in promoting access to PrEP for people who are at risk for HIV infection.

We are committed to keeping up the momentum for educating our communities about PrEP. The campaign website, www.prepforsex.org remains active with thousands of hits per month. We have added a new series of videos highlighting the voices of people who are using PrEP. These are 2 to 6 minute videos that address who is eligible for PrEP, concerns about side effects, affordability, PrEP and emotions and other topics. These videos can be used during individuals patient education sessions, during groups or even in the agency waiting room.

We are also pleased to announce that the LGBT Center has developed an innovative text messaging campaign to address barriers to PrEP. Be sure to check it out by texting prep to 69866.

Click here to view a one page poster which highlights these resources. Please feel free to make copies of the poster, display it at your agency, give it to clients, make it available in your community, include a link to www.prepforsex.org on your website and any other methods you think could help disseminate this important information.

If you have questions, please feel free to contact HIV Education and Training Programs at 518-474-3045 or hivet@health.ny.gov

 

^ Return to Top


NYS Medicaid Update: July (7-27-2016)

Posted July 27, 2016

Dear Medicaid Provider,

The Office of Health Insurance Programs of the New York State Department of Health recently got a new look and main page for the Medicaid Update. It can be viewed along with the newly approved July 2016 Medicaid Update and can better accommodate smaller devices.

Please find the full current issue as a PDF (Portable Document Format) file available to be downloaded at: http://www.health.ny.gov/health_care/medicaid/program/update/2016/jul16_mu.pdf

 

^ Return to Top


Can New York End the AIDS Epidemic? (7-18-2016)

From the The Huffington Post, July 18, 2016

The Blog, by David Sandman, President & CEO, New York State Health Foundation

In July 1981—35 years ago this month—The New York Times ran a now infamous headline: “Rare Cancer Seen in 41 Homosexuals.” The story also reported, “The cause of the outbreak is unknown, and there is as yet no evidence of contagion.” It was the first news article about a mysterious new disease that came to be the HIV/AIDS epidemic. Read the full article

 

^ Return to Top


Quick News Update from OMD AIDS Institute (7-18-2016)

Posted July 18, 2016

OMD SCREENSHOT – July 18th, 2016

Follow the 21st International AIDS Conference in Durban, South Africa online from July 18-22 at http://www.aids2016.org/The-Conference-Online

Register here for this month’s Free HIV Clinical Education Webinar “Testing, Treatment, and Prevention: The Clinician’s Role in Ending the Epidemic in New York State” on Wednesday, July 20th from 12:00-1:00PM.

Join our Voluntary Provider Directories:

Congress Passes Landmark Opioid Bill – the Comprehensive Addiction and Recovery Act (CARA) – on July 14th 2016. See details here.

New Paper in The Lancet Infectious Diseases on the Hepatitis C Treatment Access Crisis can be found here (requires subscription)

 

^ Return to Top


Antibiotic Resistance Threatens Gonorrhea Treatment (07-15-2016)

Posted July 15, 2016

Resistance to azithromycin, an antibiotic used to treat gonorrhea, is emerging, according to CDC findings published today in the Morbidity and Mortality Weekly Report.

For more information, please click here.

 

^ Return to Top


HIV Training NY: New PrEP Video and Text Messaging Resources (7-14-2016)

Posted July 14, 2016

New PrEP Video and Text Messaging Resources

Dear Colleague:
The AIDS Institute is pleased to announce two new exciting resources on Pre-Exposure Prophylaxis (PrEP) for HIV.

PrEP for Sex Video Series
This series of eight videos highlights the voices of men who are currently taking PrEP to prevent HIV infection.

Honest, forthright and insightful, these videos address the following topics:

  • Is PrEP Right for Me
  • Beginning the Process
  • Affordability
  • Remembering to Take PrEP
  • Condom Use
  • Why PrEP
  • Side Effects
  • PrEP and Emotions

Some ideas on how you can use these videos:

  1. Include them in community education programs about PrEP
  2. Run the videos in a public space at your agency
  3. Share links to the videos on your website
  4. Watch them with a client
  5. Post them on your agency Facebook page or tweet about them

You can find these videos embedded on the www.prepforsex.org website or you can check them out on YouTube at: PrEP for Sex – Video Series

PrEP Text Messaging Campaign
Text PREP to 69866 for personalized advice on getting PrEP!

The New York State LGBT Health & Human Services Network (“the Network”) has created a campaign that provides education and resources around PrEP. The campaign guides users through a pre-programed, yet personalized, conversation that helps them overcome at least 1 of 3 of the major barriers New Yorkers face to accessing PrEP: cost, eligibility or drug-to-drug interactions.

New Yorkers will text PREP to 69866, and after providing demographic information, be able to select the barrier they would like to overcome. In the process of overcoming each barrier, the user is provided with positive reinforcement messaging, curated resource referrals (links to NYSDOH sites) and 3 PrEP provider referrals (based off of their zip code). Through Mobile Commons’ customer relationship management platform, The Network is able to track each user’s conversation flow and whether they are clicking the provided resource links and numbers. The Network will also be able to schedule follow-up messaging and accrue private and secured lists for future campaign launches.

You can find this campaign mentioned on the www.prepforsex.org website. Feel free to reach out to Storm Hurwitz, Health Campaigns Specialist for the Network, at shurwitz@gaycenter.org with any questions, comments or concerns.

____________________________________
To register for any course, click on the appropriate registration link and enter your account log-in information.If you do not have an account with hivtrainingny.org, you will need to sign up for one prior to registering for a course. For help in registering, please contact the NYSDOH AIDS Institute’s HIV Education and Training Program at (518) 474-3045.

 

^ Return to Top


AIDSinfo: At-a-Glance: Updated HHS Adult and Adolescent Antiretroviral Treatment Guidelines Released (7-14-2016)

Posted July 14, 2016

The AIDSinfo At-a-Glance News and Features can be viewed by clicking here.

Included are updates on the following:

 

^ Return to Top


Governor Cuomo Announces Key Milestones Achieved Towards Ending the AIDS Epidemic in NYS by the End of 2020 (7-13-2016)

Posted July 13, 2016


Governor Cuomo Announces Key Milestones Achieved Towards Ending the AIDS Epidemic in New York State by the End of 2020.

Record Low Number of New HIV Infections

10 Percent Decrease in New Yorkers with Detectable Levels of HIV

Governor Andrew M. Cuomo today announced that the State of New York is on track to reduce the number of new HIV infections to just 750 by the end of 2020 and achieve the first-ever decrease in HIV prevalence. The number of New Yorkers with HIV at detectable levels decreased by approximately 10 percent between 2013 and 2014, and as a result, two-thirds of those with diagnosed HIV now have virus levels that are undetectable. The information comes from the latest data produced by the New York State Department of Health and also shows that the number of new HIV infections has fallen to fewer than 2,500, a record low.

To read the full press release, please click here.

 

^ Return to Top


NYS Clinical Education: New Courses, This Month in HIV, Archived This Month in HIV, Ending the HIV and STI Epidemic (7-12-2016)

Posted July 12, 2016

Please click here to view the latest update from the New York State Clinical Education Initiative.

Included are updates on the following:

  • New CE Courses
  • July This Month in HIV Testing, Treatment, and Prevention: The Clinician’s Role in Ending the AIDS Epidemic in New York State
  • This Month in HIV Archived Training Sessions and Fall 2016 Schedule Now Available!
  • Save the Date! “Ending the HIV and STI Epidemic: Perspectives from ED and Urgent Care Practice”

 

^ Return to Top


Syphilis Cases Increasing Among Women of Childbearing Age in New York City (7-12-2016)

Posted July 12, 2016

Syphilis Cases Increasing Among Women of Childbearing Age in New York City

Three-quarters of female syphilis cases are in women of color

Providers advised to screen all pregnant women for syphilis at first prenatal visit and delivery, and more often if patients are believed to be at risk

July 11, 2016 – The Health Department today issued a Health Alert to providers that emphasizes the importance of testing pregnant women for syphilis as infection rates rise in New York City (NYC). Mirroring overall trends in syphilis prevalence in the United States, rates of primary and secondary syphilis among NYC women have risen 36 percent from 2014 (32 cases) to 2015 (43 cases). There were 36 cases in the first six months of 2016. The median age of women with syphilis is 26, and the women are predominantly Black or Latina (73 percent). The increase in women is notable because syphilis predominately has affected men for the past 15 years.

To read the full press release, please click here.
 

NYC DOHMH Alert # 14 – Syphilis is increasing among women of child-bearing age in New York City, 2016

Please Share this Alert with Colleagues in Obstetrics and Gynecology, Pediatrics, Adolescent Medicine, Internal Medicine, Family Medicine, Primary Care, Dermatology, Infectious Diseases, Urgent Care, and Emergency Medicine.

  • Primary and secondary syphilis cases are increasing among young women of color in New York City
  • Test for pregnancy and treat empirically for syphilis any woman with a syphilis exposure or any woman with lesions or rash suggestive of syphilis.
  • Screen all pregnant women for syphilis at first prenatal visit and delivery
  • Bicillin-LA is the only treatment for pregnant women infected with or exposed to syphilis
  • Call 347-396-7201 (Monday-Friday, 8:30am–5pm) to determine the history of syphilis testing and treatment for your patient

Dear Colleagues,

After years of low and stable rates, primary and secondary (P&S) syphilis cases among women have begun to increase in New York City. Although the number of cases is still relatively small, rates of P&S syphilis increased 36% from 2014 (32 cases) to 2015 (43 cases), and the occurrence of 36 cases in the first 6 months of 2016 suggests that the trend will continue. The women with syphilis are young (median age, 26 years) and predominantly (73%) black or Hispanic. To prevent increases in congenital syphilis (CS), providers must identify and treat women with syphilis or syphilis exposure, and all pregnant women must be screened for syphilis in accordance with New York State law (1, 2). In the past several years, provider errors have resulted in several instances of fetal demise due to CS and, in 2016, one stillbirth.

To read the full alert, please click here.

 

^ Return to Top


HEALTHQUAL in the Joint Commission Journal on Quality and Patient Safety (7-12-2016)

Posted July 12, 2016

An Update from HEALTHQUAL International: HEALTHQUAL in the Joint Commission Journal on Quality and Patient Safety

We are pleased to announce the publication of a Tool Tutorial describing HEALTHQUAL’s National Organizational Assessment now available in the July 2016 Issue of the Joint Commission Journal on Quality and Patient Safety (Volume 42 Number 7).

HEALTHQUAL developed the national organizational assessment (NOA) of core national quality management program components to support the development and maturity of sustainable national improvement work among Ministries of Health in low- and middle-income countries as part of its capacity building activities through PEPFAR.

Read More

 

^ Return to Top


Updates from AETC Program Friends & Colleagues (7-11-2016)

Posted July 11, 2016

Updates from AETC Program Friends & Colleagues are now available by clicking here.

Included are updates on the following:

  • PrEP Education for Youth-Serving Primary Care Providers Toolkit
  • HHS Announces New Actions to Combat Opioid Epidemic
  • Zika Virus: Information for Clinicians Slide Set
  • Serostatus Matters CME Program
  • Addressing Organizational Barriers to HIV Care: Lessons Learned from AIDS United’s Positive Charge Initiative (webinar) – July 19, 2016, 2:00-3:00 PM ET
  • 3rd Great Plains Area Indian Health Service Public Health Training Conference – August 4-5, 2016, Bismarck, ND
  • Awareness Days

 

^ Return to Top


Quick News Update from OMD AIDS Institute (7-11-2016)

Posted July 11, 2016

OMD SCREENSHOT – July 11th, 2016

 

^ Return to Top


PrEP Education for Youth-Serving Primary Care Providers Toolkit (7-7-2016)

Posted July 7, 2016

The Sexuality Information and Education Council of the United States (SIECUS) is pleased to release the PrEP Education for Youth-Serving Primary Care Providers Toolkit, a first of its kind resource focused on supporting primary care providers (PCPs) serving youth.

The Toolkit combines the many excellent existing resources about PrEP and HIV with new content developed by experts in the field. The Expert Work Group, convened by SIECUS, focused on addressing issues surrounding PrEP delivery and contributed to the development of this online resource to support primary care providers in educating, counseling, and offering PrEP to their young patients.

Focusing on concerns from a provider perspective and provision of care to young patients disproportionately affected by HIV, the Toolkit includes tools and resources that PCPs can use in delivering PrEP care or in learning about particular aspects of PrEP delivery to youth:

  • Clinical Tools
  • Billing for PrEP
  • HIV, Stigma, and Social Determinants of Health
  • Youth and HIV Laws and Policies
  • Additional Resources

For more information, please click here.

 

^ Return to Top


Updates from AETC Program Friends & Colleagues (7-5-2016)

Posted July 5, 2016

Updates from AETC Program Friends & Colleagues are now available by clicking here.

Included are updates on the following:

  • Updated AETC Program Description Slide Set
  • Building Patient-Centered Medical Homes for Lesbian, Gay, Bisexual, and Transgender Patients and Families (report)
  • FDA Approves Epclusa for Treatment of Chronic Hepatitis C Virus Infection
  • The Stigma of HIV Prevention (webinar) – July 11, 2016, 1:30-3:00 PM ET
  • Indian Health Service (IHS) Announces Funding Opportunity to Promote HIV/AIDS Prevention and Engagement in Care
  • Save-the-Date: Ryan White HIV/AIDS Program (RWHAP) and Pre-Exposure Prophylaxis (PrEP) Webcast – August 2, 2016, 1:00-3:00 PM ET
  • Awareness Days

 

^ Return to Top


HIV Training NY: Choosing Life: Empowerment, Actions, Results! (7-5-2016)

Posted July 5, 2016

Choosing Life: Empowerment, Actions, Results!

The CLEAR (Choosing Life: Empowerment, Actions, Results!) training has been scheduled to take place in Rochester @ CHBT on July 19-22, 2016 from 8:30 am – 4:30 pm each day.

CLEAR is an evidence-based health promotion intervention (EBI) for males and females ages 16 and older living with HIV/AIDS, and for high-risk HIV-negative individuals.

CLEAR is a client-centered program delivered one-to-one using cognitive behavior techniques to change behavior. The intervention provides clients with the skills necessary to be able to make healthy choices for their lives.

With the help of prevention counselors, CLEAR clients develop a personal life goal and an individual prevention plan, via 5 core skill sessions and 21 menu sessions in order to promote long-term behavior change.

Here is the direct registration link for CLEAR: https://hivtrainingny.org/Account/LogOn?crs=1868
____________________________________

To register for any course, click on the appropriate registration link and enter your account log-in information. If you do not have an account with hivtrainingny.org, you will need to sign up for one prior to registering for a course. For help in registering, please contact the NYSDOH AIDS Institute’s HIV Education and Training Program at (518) 474-3045.

 

^ Return to Top


AIDSinfo: At-a-Glance: FDA Updates Darunavir Labeling (7-1-2016)

Posted July 1, 2016

The AIDSinfo At-a-Glance News and Features can be viewed by clicking here.

Included are updates on the following:

 

^ Return to Top


NQC e-Newsletter: The Quality Academy Expands (7-1-2016)

Posted July 1, 2016

Please click here to view the e-Newsletter from the National Quality Center (NQC).

 

^ Return to Top


The Conspicuous Gap Between HIV Care and HIV Public Health, John G. Bartlett, MD (Medscape, June 20, 2016) (6-30-2016)

Posted June 30, 2016

The Conspicuous Gap Between HIV Care and HIV Public Health, John G. Bartlett, MD (Medscape, June 20, 2016)

 

^ Return to Top


NYC Health: Update on Zika Virus Infection in New York City (6-29-2016)

Posted June 29, 2016

2016 NYC DOHMH Advisory #16: Update on Zika Virus Infection in New York City

Please share with your colleagues in Obstetrics/Gynecology, Internal Medicine, Family Medicine, Emergency Medicine, Urgent Care, Pediatrics, Infectious Disease, and Neurology:

  • As of June 24, 2016, 233 Zika virus infections have been diagnosed among New York City residents, including 24 pregnant women.
  • Advise pregnant patients to defer travel to Zika virus-affected areas until the end of their pregnancy.
  • Take a travel history from all pregnant women and patients with Zika compatible symptoms.
  • RT-PCR testing to detect Zika virus RNA in serum and urine is now available at several commercial laboratories.
  • If testing a pregnant woman for Zika infection, serology must be performed and remains available only at NYC’s Public Health Laboratory and New York State Wadsworth Center.
  • Call the NYC Health Department at 866-692-3641 to:
    • Request Zika testing for NYC residents or assistance in interpreting test results.
    • Report Zika-positive cases diagnosed by a commercial laboratory.

To view the entire 2016 NYC DOHMH Advisory #16: Update on Zika Virus Infection in New York City, please click here.

 

^ Return to Top


NYS Medicaid Update: June (6-29-2016)

Posted June 29, 2016

Dear Medicaid Provider,

The Office of Health Insurance Programs of the New York State Department of Health recently got a new look and main page for the Medicaid Update. It can be viewed along with the newly approved June 2016 Medicaid Update and can better accommodate smaller devices.

Please find the full current issue as a PDF (Portable Document Format) file available to be downloaded at: http://www.health.ny.gov/health_care/medicaid/program/update/2016/jun16_mu.pdf

-Or-

Go straight to an article or topic that pertains to you, by using your browser, when you select from the current issue’s table of contents linked here (you may need to double-click or right-click-open-hyperlink to jump straight to the article):

 

^ Return to Top


Quick News Update from OMD AIDS Institute: Bicillin L-A (6-28-2016)

Posted June 28, 2016

Special Announcement

The only manufacturer of Bicillin L-A (penicillin G benzathine) continues to report a manufacturing delay and does not expect to return to normal supply until the middle of July, 2016. Information is available at the FDA Drug Shortage website. Penicillin G benzathine is the recommended treatment for syphilis and the only recommended treatment for pregnant women infected with or exposed to syphilis. If product supply becomes critical (supply of three weeks or less), contact the Pfizer Supply Continuity Team at 844-804-4677 for an emergency supply.

The Centers for Disease Control and Prevention (CDC) suggest the following to conserve supply:

  1. Refrain from using penicillin G benzathine to treat other infectious conditions for which other effective antimicrobials are readily available;
  2. Adhere to the recommended dosing of 2.4 million units IM of penicillin G benzathine for the treatment of primary, secondary and early latent syphilis as indicated in the 2015 CDC STD Treatment Guidelines. Additional doses to treat early syphilis infections do not enhance efficacy.
  3. Direct questions about syphilis clinical management to the Clinical Education Initiative STD Center of Excellence by calling 866-637-2342.

 

See recorded CDC Webinar Series:
Overview of the CDC Guideline for Prescribing Opioids for Chronic Pain

 

^ Return to Top


FDA Approves Epclusa for Treatment of Chronic Hepatitis C Virus Infection (6-28-2016)

Posted June 28, 2016

On June 28, 2016, FDA approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced liver disease). For patients with moderate to severe cirrhosis (decompensated cirrhosis), Epclusa is approved for use in combination with the drug ribavirin. Epclusa is a fixed-dose combination tablet containing sofosbuvir, a drug approved in 2013, and velpatasvir, a new drug, and is the first to treat all six major forms of HCV.

To view the full press announcement, please click here.

 

^ Return to Top


NYS Clinical Education: New CE Courses, HepCure Webinar, STD/HIV Risks & Screening (6-28-2016)

Posted June 28, 2016

Please click here to view the latest update from the New York State Clinical Education Initiative.

Included are updates on the following:

  • New CE Courses
  • Registration Now Open! The HepCure Tele-Education Webinar Series presents Hepatitis C Treatment in the Active Substance User
  • STD/HIV Risks & Screening for Black Men who have Sex with Men
  • This Month in HIV Testing, Treatment, and Prevention: The Clinician’s Role in Ending the AIDS Epidemic in New York State
  • CEI Line

 

^ Return to Top


Ryan White HIV/AIDS Program and Pre-Exposure Prophylaxis (PrEP) Program Letter (6-27-2016)

Posted June 27, 2016

HRSA HAB has released a letter in support of PrEP as a prevention tool against HIV transmission, to align with the National HIV/ AIDS Strategy: Updated to 2020 Goal 1: Reduce New Infections and calls upon federal agencies to implement PrEP within their programs. The letter encourages Ryan White HIV/AIDS Program (RWHAP) recipients and providers to leverage the RWHAP infrastructure to support PrEP services within the parameters of the RWHAP legislation.

Link to read the full letter

 

^ Return to Top


Updates from AETC Program Friends & Colleagues (6-27-2016)

Posted June 27, 2016

Updates from AETC Program Friends & Colleagues are now available by clicking here.

Included are updates on the following:

  • Ryan White HIV/AIDS Program and Pre-Exposure Prophylaxis (PrEP) Program Letter
  • HIV Health Improvement Affinity Group
  • The Afforadable Care Act (ACA) and People with HIV: An Update
  • Building Respect for LGBT Older Adults E-Learning: Supplemental Information for Staff
  • Back to the Basics: Primary and Behavioral Health Care Integration (webinar) – July 11, 2016, 2:00-3:00 PM EDT
  • HPV, Telehealth, Opioid Prescribing, and more….Public Health Webinar Series
  • 5th Annual Rural HIV Research and Training Conference – September 9-10, 2016, Savannah, GA
  • Awareness Days

 

^ Return to Top


Governor Cuomo Announces All HIV-Positive Individuals in New York City to Become Eligible For Housing, Transportation and Nutritional Support: Read Press Release (6-23-2016)

Posted June 23, 2016

Read the press release: Governor Cuomo Announces All HIV-Positive Individuals in New York City to Become Eligible for Housing, Transportation and Nutritional Support

 

^ Return to Top


NYSDOH Announces New Policy Defining Program Eligibility by HIV Status (6-23-2016)

Posted June 23, 2016

Defining Program Eligibility by HIV Status

New York State Department of Health Policy Statement, June 23, 2016

In past decades, when there was little information about HIV and AIDS, health care providers made decisions about when to initiate care and treatment for persons infected with HIV based upon the presence of certain symptoms, such as HIV-associated dementia, HIV nephropathy, and other HIV-related malignancies and conditions. In the absence of such conditions, treatment was initiated when a patient’s CD4 count fell below 350 cells/mm3 .

Today, it is common knowledge that, to achieve viral load suppression, care and treatment should begin immediately upon diagnosis of HIV. For this reason, HIV status is the current standard by which determinations are made for eligibility: to receive care and treatment in a State-designated AIDS center hospital or HIV Primary Care Program clinic; to enroll in an HIV Special Needs Plan (HIVSNP) or health home; and to participate in HIV/AIDS-related programs, such as the AIDS Adult Day Health Care Programs. Using HIV diagnosis as the standard for determining when to begin HIV care and treatment is consistent with the recommendations of the US Centers for Disease Control and Prevention.1 This message is, and has been, reflected in all communications of the New York State AIDS Institute.2

The purpose of this Policy Statement is to formally reiterate that the New York State Department of Health AIDS Institute’s clinical guidelines recommend that HIV-related care and treatment be initiated immediately upon diagnosis. Accordingly, to the extent permitted by law, the terms “clinical/symptomatic HIV illness or AIDS”, “AIDS or HIV-related illness,” and other similar terms shall mean laboratory-confirmed HIV diagnosis.

This Policy Statement aligns with Governor Andrew M. Cuomo’s Ending the AIDS Epidemic (ETE) initiative, which seeks to prevent the transmission of HIV and decrease the incidence of persons infected with HIV. The ETE initiative also includes the Governor’s recent negotiation of new legislation that will expand access to postexposure prophylaxis (PEP), as well as other legislation and initiatives focused on improving the health of currently HIV-infected persons and preventing HIV transmission in New York State.

———————————

1. The Centers for Disease Control and Prevention’s guidelines can be found at https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/0.

2. Additional AIDS Institute guidelines can be found at http://www.hivguidelines.org/clinical-guidelines/adults/antiretroviraltherapy/#III. WHEN TO INITIATE ART.

 

^ Return to Top


Governor Cuomo Signs Legislation to Combat the Heroin and Opioid Crisis (6-22-2016)

Posted June 22, 2016

Comprehensive Legislative Package Limits Opioid Prescriptions from 30 to 7 Days, Requires Mandatory Prescriber Education on Pain Management to Stem the Tide of Addiction, Eliminates Burdensome Insurance Barriers to Treatment

Expands Supports for New Yorkers in Recovery, Increases Treatment Beds by 270 and Adds 2,335 Program Slots for Substance Use Disorder in New York

To learn more, please visit https://www.governor.ny.gov/news/video-photos-transcript-governor-cuomo-signs-legislation-combat-heroin-and-opioid-crisis

 

^ Return to Top


Introducing the New AETC National Coordinating Resource Center Website (6-22-2016)

Posted June 22, 2016

We are pleased to announce that the newly redesigned and expanded AETC NCRC website (aidsetc.org) is now LIVE! The website has been updated to meet the needs of our growing audience of healthcare professionals interested in building capacity to improve care delivery to people living with HIV and those at risk throughout the U.S. and its territories. With the extent of information available on the website this was no easy task, but in response to website user feedback, a more engaging and user-friendly site was created for new and returning visitors alike.

You’ll notice new branding images and visual identity elements have been incorporated throughout to enliven and unify the AETC Program and its grantees. Training topics have been reorganized to guide users to their destination more efficiently, and a new responsive design makes the site clear and legible from any viewing device. The website is also accessibility compliant. Our technical team monitors the site regularly to prevent and remove barriers to accessibility for people with disabilities, and advocates for content authors and producers to follow standards when writing and preparing new information for publication in all formats.

We hope that you will take some time to familiarize yourself with the new site. The AETC NCRC is committed to providing high-quality information and resources for your training needs, while improving your user experience. The site will continue to grow so please do not hesitate to contact us if you have trouble accessing any of the content, or to provide feedback about the new features. We look forward to hearing your thoughts.

 

^ Return to Top


HIV Training NY: Peer Worker Employment Opportunities LISTSERV (6-22-2016)

Posted June 22, 2016

Announcing a FREE Employment Opportunities LISTSERV for HIV, HCV and Harm Reduction Peer Workers

Due to public demand for a way to connect agencies seeking to hire Peer Workers with interested applicants, the NYS Department of Health AIDS Institute is establishing the Peer Worker Employment Opportunities LISTSERV. The LISTSERV is free of cost for both employers and Peer Workers seeking employment.

How will the LISTSERV work?

  • Employers will be invited to send information about available Peer Worker positions to the AIDS Institute at: hivet@health.ny.gov
  • Peer Workers interested in learning about available positions will sign up to participate in the LISTSERV. The names of people who sign up for the LISTSERV are never publically displayed
  • The AIDS Institute will compile the available positions and send them out by email periodically through the Peer Worker Employment Opportunities LISTSERV
  • The LISTSERV will include the following information about each available position: name of employer and location; short description of job; required qualifications; how to apply; dates when applications are due; link to agency website with the job posting

How can I sign up for the Peer Worker Employment Opportunities LISTSERV?

Peer workers (HIV/HCV/Harm Reduction) looking for employment, or anyone interested in receiving the announcements, can sign up for the LISTSERV by visiting www.hivtrainingny.org, typing their email address into the box at the bottom of the right column titled Peer Worker Employment Opportunities LISTSERV and completing the fields on the page that comes up.

Do I have to be an AIDS Institute Certified Peer Worker to join the LISTSERV?
No. Anyone may join the LISTSERV, whether you are certified, working toward certification or have no plans to ever become certified.

How will the Peer Worker Employment Opportunities LISTSERV help my agency?
If your agency has an open position for a Peer Worker, you can send information about the position to the AIDS Institute who will announce the employment opportunity via the LISTSERV. All Peer Workers who have signed up on the LISTSERV will receive the notification. This will help ensure you receive a strong pool of applicants for any open position.

How can I have my job opportunities announced via the LISTSERV?
Send the following information about the position to: hivet@health.ny.gov

  • name of employer and location;
  • short description of job;
  • required qualifications;
  • how to apply and dates when applications are due;
  • link to agency website with the posted position.

How often will LISTSERV announcements be sent out?
Announcements will be sent out within the 3rd business day of confirmed receipt of the request for posting. Please consider this when you establish dates for when applications are due.

Will the LISTSERV be only open to AIDS Institute Certified Peer Workers?
No. Anyone may join the LISTSERV whether they are currently certified, pursuing certification or never planning to pursue certification. If your agency is seeking a Certified Peer Worker, please state that when describing required qualifications.

For additional information on AIDS Institute Peer Certification, visit our website: https://www.hivtrainingny.org/Home/PeerCertification

Questions about the LISTSERV? Contact Leslie Osta at leslie.osta@health.ny.gov or 518-474-3045

 

^ Return to Top


SMAIF Supports HRSA Grant Opportunity to Address HIV Care Continuum in Southern Metropolitan Areas (6-22-2016)

Posted June 22, 2016

The south lags behind much of the rest of the nation on a number of key outcomes including viral suppression and survival among people living with HIV. To help address this, the Health Resources and Services Administration (HRSA) has announced a funding opportunity for a new program: Ryan White HIV/AIDS Program Building Care and Prevention Capacity: Addressing the HIV Care Continuum in Southern Metropolitan Areas. [READ MORE]

 

^ Return to Top


CDC Health Update: CDC Recommendations for Subsequent Zika IgM Antibody Testing (6-21-2016)

Posted June 21, 2016

CDC Recommendations for Subsequent Zika IgM Antibody Testing

Summary
Testing for Zika virus infection using real-time reverse-transcription polymerase chain reaction (rRT-PCR) molecular assays is now commercially available. When requesting Zika rRT-PCR testing from a commercial laboratory, providers should be aware that commercial laboratories performing rRT-PCR currently do not also offer Zika IgM enzyme-linked immunosorbent assay (ELISA) or confirmatory serologic testing (plaque reduction neutralization test, or PRNT). Therefore, if possible, providers should store a serum aliquot for subsequent Zika IgM ELISA testing if the rRT-PCR assay is negative. Otherwise, collection of an additional serum sample may be necessary.

To download and view a PDF of the CDC Health Update, please click here.

 

^ Return to Top


CHI: Addressing Alcohol and Drug Use: An Integral Part of Primary Care (06-20-2016)

Posted June 20, 2016

  • Unhealthy alcohol and drug use are treatable, but often go unrecognized and unaddressed in primary care.
  • Incorporate a continuum of substance use health services into your practice.
  • Use electronic health records and the clinical care team to facilitate service delivery.

The full PDF version can be accessed by clicking here.

 

^ Return to Top


Updates from AETC Program Friends & Colleagues (6-20-2016)

Posted June 20, 2016

Updates from AETC Program Friends & Colleagues are now available by clicking here.

Included are updates on the following:

  • HIV & Hepatitis Health Disparities Update: June 2016
  • HIV in the Southern United States: CDC Issue Brief and Infographic
  • AIDSVu Annual Launch (webinar) – June 24, 2016, 12:00 -1:00 PM ET
  • New Analysis of HIV Prevention Among MSM
  • HIV Cure: Where Are We Now? (webinar) – July 26, 2016, 1:00-2:30 PM ET/10:00-11:30 AM PT
  • Behavioral Health Integration: Beyond the Basics (training sessions)
  • 34th Gay and Lesbian Medical Association (GLMA) Annual Conference on LGBT Health – September 14 -17, 2016, St. Louis, Missouri
  • 2016 Transgender Health Conference: Advancing Excellence in Transgender Health – September 23-24, 2016, Boston, MA
  • Awareness Days

 

^ Return to Top


FDA HIV/AIDS Update: Updates for Prezista (Darunavir) for Use in Pregnant Women (06-17-2016)

Posted June 17, 2016

On June 17, 2016, FDA approved updates to the Prezista (darunavir) for use in pregnant women. The major changes can be viewed by clicking here.

 

^ Return to Top


AIDSinfo: At-a-Glance: Seeking Participants for AIDSinfo HIV/AIDS Guidelines App Usability Study (6-17-2016)

Posted June 17, 2016

The AIDSinfo At-a-Glance News and Features can be viewed by clicking here.

Included are updates on the following:

 

^ Return to Top


The Clinical Pathway Track of the 2016 National Ryan White Conference on HIV Care & Treatment (6-16-2016)

Posted June 16, 2016

The following announcement is on behalf of the International Antiviral Society-USA (IAS-USA) regarding the Clinical Pathway Track of the 2016 National Ryan White Conference on HIV Care & Treatment:

Dear Colleagues,

This year the Ryan White Clinical Conference is being held as a track (Clinical Pathway) at the 2016 National Ryan White Conference on HIV Care & Treatment (NRWC). The Clinical Pathway track is restricted to 400 clinical decision makers who work in Ryan White HIV/AIDS Program–funded clinics or programs. General session lectures and small-group workshops will be held August 23 to August 25, 2016. As the continuing medical education sponsor, IAS–USA is organizing the Clinical Pathway track with the AIDS Education and Training Center National Coordinating Resource Center and the Health Resources and Services Administration, HIV/AIDS Bureau.

If you are an experienced HIV clinical decision maker (ie, physician, nurse practitioner, or physician assistant) in a Ryan White HIV/AIDS Program–funded clinic or program and would like to attend the Clinical Pathway track, the application can be found here. Please note that you must first be a confirmed registrant of the NRWC to apply to attend the Clinical Pathway track. Please forward this e-mail to colleagues who may fit the criteria.

For more information about the Clinical Pathway track please visit the website. If you have any questions, you can contact us by e-mail at info@iasusa.org or by phone at 415-544-9400 during regular business hours of 8:30 AM to 5:30 PM PT.

 

^ Return to Top


AETC ShareSpot: HIV and Heart Disease – NIH Explores the Connection (6-15-2016)

Posted June 15, 2016

Heart disease among HIV-infected individuals is emerging as a major public health problem despite effective treatments that suppress viral load. People living with HIV are 50 to 100% more likely to develop heart disease, including heart attack and stroke, compared with people who do not have HIV-infection. Currently, there are no approved strategies for heart disease prevention tailored to people living with HIV. REPRIEVE, which stands for a Randomized Trial to Prevent Vascular Events in HIV, is a large-scale randomized clinical research trial looking to change that. The trial will test whether a daily dose of pitavastatin reduces the risk of heart disease among HIV-infected individuals. Providers, your client may qualify to participate in REPRIEVE if he or she:

  • Is HIV-positive
  • Is between the ages of 40 and 75
  • Has been on antiretroviral therapy (ART) for at least 6 months prior to study entry
  • Has no history of heart disease (including heart attack or stroke)
  • Is not currently using a statin drug
  • Has a low to moderate risk for developing heart disease, as determined by the American College of Cardiology/American Heart Association Risk Calculator

Read more about this clinical trial in our latest ShareSpot post “HIV and Heart Disease – NIH Explores the Connection,” by Sarah Read, MD, and Karin Klingman, MD, both from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, and consider recommending participation in this historic study to help address the growing problem of HIV-related heart disease. Visit reprievetrial.org or call 1-877-29-HEART for more information.

 

^ Return to Top


WHO: Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection (6-15-2016)

Posted June 15, 2016

Recommendations for a public health approach – Second edition

Overview
These guidelines provide guidance on the diagnosis of human immunodeficiency virus (HIV) infection, the use of antiretroviral (ARV) drugs for treating and preventing HIV infection and the care of people living with HIV. They are structured along the continuum of HIV testing, prevention, treatment and care.
This edition updates the 2013 consolidated guidelines on the use of antiretroviral drugs following an extensive review of evidence and consultations in mid-2015, shared at the end of 2015, and now published in full in 2016. It is being published in a changing global context for HIV and for health more broadly.

Please click here for more information.

 

^ Return to Top


CDC Advisory: Alert to US Healthcare Facilities: First mcr-1 Gene in E coli Bacteria found in a Human in the US (6-14-2016)

Posted June 14, 2016

The NYC Health Department is providing this Alert from the Centers for Disease Control and Prevention regarding the first mcr-1 Gene in E. coli Bacteria found in a Human in the United States. If you suspect or confirm a case with the MCR-1 gene in a NYC resident, please call the Health Departments Provider Access Line at 1-866-692-3641.

Alert to U.S. Healthcare Facilities: First mcr-1 Gene in E. coli Bacteria found in a Human in the United States

Summary
The Centers for Disease Control and Prevention (CDC) is collaborating in a coordinated public health response to the Department of Defense (DoD) announcement on May 26 of the first mcr-1 gene found in bacteria from a human in the United States (http://aac.asm.org/content/early/2016/05/25/AAC.01103-16.full.pdf+html). Escherichia coli (E. coli) bacteria carrying the mcr-1 gene were found in a urine sample from a person in Pennsylvania with no recent travel outside of the United States who presented to a clinic with a urinary tract infection. The mcr-1 gene makes bacteria resistant to the antibiotic colistin, which is used as a last-resort drug to treat patients with infections caused by multidrug-resistant bacteria, including carbapenem-resistant Enterobacteriaceae (CRE). The mcr-1 gene exists on a plasmid, a small piece of DNA that is capable of moving from one bacterium to another, potentially spreading antibiotic resistance to other bacterial species. CDC is issuing this HAN notice as a reminder to U.S. healthcare facilities about recommendations to prevent antibiotic resistant infections and alert them to additional recommendations for detecting and reporting bacteria with the mcr-1 gene.

To download and view a PDF of the CDC Update, please click here.

 

^ Return to Top


NYS Clinical Education: New CE Courses, This Month in HIV Webinar, HIV Cure Symposium, 2nd Annual STD Conference (6-14-2016)

Posted June 14, 2016

Please click here to view the latest update from the New York State Clinical Education Initiative.

Included are updates on the following:

  • New CE Courses
  • June This Month in HIV Webinar HIV Prevention for Positives and Negatives, June 15
  • Registration Now Open! New York State 2016 HIV Cure Symposium: Connecting Research to Clinical Practice, June 20
  • 2nd Annual New York State STD Conference Finger Lake Region, June 24

 

^ Return to Top


Updates from AETC Program Friends & Colleagues (6-13-2016)

Posted June 13, 2016

Updates from AETC Program Friends & Colleagues are now available by clicking here.

Included are updates on the following:

  • Updates to Perinatal Guidelines Released
  • NJ HIVLinks – Summer 2016
  • The 2015 Youth Risk Behavior Surveillance System (YRBSS) Data Released
  • Key Issues Ahead of the International AIDS Conference in South Africa (webinar) – June 21, 2016, 10:00-11:00 AM ET
  • CDC Guideline for Prescribing Opioids for Chronic Pain (webinar) – June 22, 2016, 2:00-3:00 PM ET
  • Reducing Opioid Overdose Mortality: Role of Community-Administered Naloxone (webinar) – June 23, 2016, 12:00-1:30 PM ET
  • Real-Time Clinician Consultation Services for Substance Use Management (webinar) – June 30, 2016, 5:00-6:00 PM ET
  • Call for Papers: Special Issue on Mental Health & Substance Use Issues in HIV Infection
  • Awareness Days

 

^ Return to Top


NQC e-Newsletter: Impact of the in+care Campaign (6-9-2016)

Posted June 9, 2016

Please click here to view the e-Newsletter from the National Quality Center (NQC).

 

^ Return to Top


AETC Program Quarterly Newsletter - Summer 2016 (6-8-2016)

Posted June 8, 2016

The AETC Program Quarterly Newsletter – Summer Edition is now available. It can be viewed here, or accessed via the AETC National Coordinating Resource Center website here.

 

^ Return to Top


AIDSinfo: At-a-Glance: Updates to the HHS Perinatal Guidelines Released (6-7-2016)

Posted June 7, 2016

The AIDSinfo At-a-Glance News and Features can be viewed by clicking here.

Updates to the HHS Perinatal Guidelines Released

The Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States (Perinatal Guidelines) were updated on June 7, 2016.

Appendix B: Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy and Table 7: Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy were revised to incorporate new data and publications, Food and Drug Administration drug label changes, and new fixed-dose combination formulations.

In Appendix B and Table 7, updates were made to the following drugs: atazanavir, dolutegravir, emtricitabine, fosamprenavir, indinavir, lamivudine, nelfinavir, nevirapine, rilpivirine, ritonavir, saquinavir, stavudine, tenofovir disoproxil fumarate, and tipranavir.

For more information, please see What’s New in the Guidelines.
 

Seeking Participants for AIDSinfo HIV/AIDS Guidelines App Usability Study

AIDSinfo is conducting an evaluation of the recently released AIDSinfo HIV/AIDS Guidelines app. The app, which is available for iOS and Android devices, provides access to the federally approved HIV/AIDS medical practice guidelines. The purpose of the evaluation is to assess the design and functionality of the app. Results from this evaluation will shape and inform future enhancements to the app.

If you are a health care professional and would like to help evaluate the app, please click here to fill out a preliminary screener. Those who are selected to participate will be compensated.

 

^ Return to Top


Updates from AETC Program Friends & Colleagues (6-6-2016)

Posted May 31, 2016

Updates from AETC Program Friends & Colleagues are now available by clicking here.

Included are updates on the following:

  • New AIDS Education & Training Center (AETC) Program Marketing Materials
  • Updated! Drugs that Fight HIV-1: A Reference Guide for Prescription HIV-1 Medications
  • Exploring Rural and Urban Mortality Differences (webinar) – June 8, 2016, 1:00-2:00 PM ET
  • Syphilis among Men who have Sex with Men (MSM): Clinical Care and Public Health Reporting (webinar) – June 9, 2016, 2:00-3:00 PM ET
  • New Investigational Approaches to HIV Treatment (webinar) – June 14, 2016, 1:00-2:30 PM ET
  • Pre-Exposure Prophylaxis (PrEP) Listening Session: Open Call for Speakers – June 20, 2016, 1:30-3:00 PM ET
  • Genital Dermatology 101: Below-the-Belt Basics (webinar) – June 23, 2016, 3:30-4:30 PM ET
  • Connecting Recently Incarcerated People Living with HIV (PLWH) to Health Coverage and Care (webinar) – June 23, 2016, 3:00-4:15 PM ET
  • Awareness Days

 

^ Return to Top


Statement by the President on the 35th Anniversary of HIV/AIDS in America (6-5-2016)

Posted June 5, 2016

On June 5, 1981, the Centers for Disease Control and Prevention published a report on what would later be understood as the first documented cases of AIDS. The past 35 years tell a story that bends from uncertainty, fear, and loss toward resilience, innovation, and hope.

Please click here to view the entire statement.

 

^ Return to Top


New & Updated HCV Fact Sheets: Adherence, Diagnostics, & Treatment (6-5-2016)

Posted June 5, 2016

Treatment Action Group has just released a new hepatitis C fact sheet on Zepatier, and updated fact sheets on Sovaldi, Viekira Pack, Harvoni, and Daklinza with new data and treatment guidelines. They are available in English and Spanish. The full set includes:

  • adherence,
  • diagnostics, and
  • treatment (Sovaldi, Olysio, Viekira Pak, Harvoni, Daklinza, Zepatier, and ribavirin).

PDFs of our fact sheets are available at: http://www.treatmentactiongroup.org/hcv/factsheets.

 

^ Return to Top


AIDSinfo: At-a-Glance (6-3-2016)

Posted June 3, 2016

The AIDSinfo At-a-Glance News and Features can be viewed by clicking here.

Included are updates on the following:

 

^ Return to Top


NYS Medicaid Update: May (6-2-2016)

Posted June 2, 2016

Dear Medicaid Provider,

The Office of Health Insurance Programs of the New York State Department of Health has a new look and main page for the Medicaid Update. It is being released along with the newly approved May 2016 Medicaid Update and can better accommodate smaller devices.

Please find the full current issue as a PDF (Portable Document Format) file available to be downloaded at: http://www.health.ny.gov/health_care/medicaid/program/update/2016/may16_mu.pdf

-Or-

Go straight to an article or topic that pertains to you, by using your browser, when you select from the current issue’s table of contents linked here (you may need to double-click or right-click-open-hyperlink to jump straight to the article):

 

^ Return to Top


Statement from FDA Commissioner Robert Califf, M.D. on the Release of the Final Individual Patient Expanded Access Form (6-2-2016)

Posted June 2, 2016

Today, the U.S. Food and Drug Administration finalized its efforts to streamline the process used by physicians to request expanded access, often called “compassionate use,” to investigational drugs and biologics for their patients. As a physician, I understand the importance of being able to access investigational treatments for a patient when there are no other options to treat their serious disease or condition.

To view the FDA Press Announcement, please click here.

 

^ Return to Top


AETC ShareSpot: Accessibility: The Bigger Picture (6-2-2016)

Posted June 2, 2016

Providing an accessible website means that you are removing barriers for users who have limited vision, hearing, and mobility to access your information and resources. The Americans with Disabilities Act requires that you create accessible web content; however, the task of improving your website to meet the requirements and needs can seem overwhelming. A new ShareSpot post, “Accessibility: The Bigger Picture” by Mary Salome, Production Manager at the University of California San Francisco Center for HIV Information, provides strategies and tips for starting the process of improving your website. In support of this story – and to further illustrate the importance of website accessibility for all users, we developed an infographic that offers some perspective about how many adults are living with disabilities in the Unites States, and how their online experience can be improved with simple changes. Visit ShareSpot to read the full story, and look for future accessibility-related posts that will focus on making specific formats compliant, like slide presentations and PDF documents, for example.

 

^ Return to Top


HIV and HCV Archived Recordings, Albany Medical College, Division of HIV Medicine (6-1-2016)

Posted June 1, 2016

Watch Albany Medical College clinical education programs on your time.

Visit our Livestream website to view online archived recordings at your convenience. Once you are on this web page, scroll down to see all our archived recordings.

Click here to visit our Livestream website.

 

^ Return to Top


NYS Clinical Education: New CE Courses, Treatment for Hepatitis C, and More (6-1-2016)

Posted June 1, 2016

Please click here to view the latest update from the New York State Clinical Education Initiative.

Included are updates on the following:

  • New CE Courses
  • Treatment for Hepatitis C: New Tests, New Drugs, and New Recommendations, June 9
  • June This Month in HIV Webinar HIV Prevention for Positives and Negatives, June 15
  • Registration Now Open! New York State 2016 HIV Cure Symposium: Connecting Research to Clinical Practice, June 20
  • 2nd Annual New York State STD Conference Finger Lake Region, June 24
  • Talk to us! Share your ideas and needs through the CEI Needs Assessment Survey

 

^ Return to Top


HIV Training NY: NYSDOH AI Peer Certification Process - Informational Session in Harlem (6-1-2016)

Posted June 1, 2016

The New York State Department of Health AIDS Institute (AI) is pleased to announce an opportunity for those interested in Peer Certification to learn more about the process and requirements. To become certified, Peer Workers must:

  • Complete foundational/readiness training or submit a personal statement;
  • Complete 90 hours of Peer Worker training from the Peer Worker Course Catalogue;
  • Have a satisfactory supervisor’s evaluation on a 500-hour practicum;
  • Agree to follow the AI Peer Worker code of ethics; and
  • Pass a knowledge exam.

As we near closer to certifying our first round of peers, the AI Peer Certification Team is visiting sites to offer informational sessions on the process and requirements for certification, as well as answer questions for those who are in the process of being certified.

Topic: New York State Department of Health AIDS Institute Peer Certification Process – Informational Session
Date: Friday, June 10, 2016
Time: 10:30am-12:30pm
Location: Harlem Hospital, Ronald H. Brown Building – 46 West 137th St Room 3701, New York, NY 10037

https://hivtrainingny.org/Account/LogOn?crs=1888

This 2 hour presentation will provide overview of the process and requirements for AIDS Institute Certification of Peer Workers and provide a step-by step walk through of the process for submitting an application for certification. There will be time for Q&A with members of the AIDS Institute Peer Certification Team.

By the end of this webcast, participants will be able to:

  • State at least three benefits of Peer Certification
  • State the three tracks for AIDS Institute Peer Worker Certification (HIV, HCV, Harm Reduction) and who is eligible to apply for certification
  • Recall the purpose of foundational training for Peer Workers and the option of completing a personal statement in lieu of foundational training
  • Identify the core and specialized training requirements for AIDS Institute Peer Worker certification
  • Recall the requirement for signing and uploading the required Code Of Ethics attestation
  • Recall the requirement for completing a practicum or work experience and uploading a satisfactory supervisor evaluation
  • Recall the requirement for passing a knowledge test and state basic features of the testing process
  • Navigate the on-line application system to begin the process of submitting an application for certification
  • Recall resources and trainings that are available online for both peer workers, their supervisors and agency leadership

Intended Audience:
Peer workers pursuing AIDS Institute certification, supervisors of Peer Workers, and interested others.

The AI plans to schedule additional informational sessions throughout NYC and upstate. Stay tuned for more opportunities to attend a session near you.

Questions? Call 518-474-3045

 

^ Return to Top


Tools to Help Individuals Locate PrEP Prescribers (6-1-2016)

Posted June 1, 2016

More and more, individuals are learning about the potential impact of HIV pre-exposure prophylaxis (PrEP). As awareness grows, so does the number of individuals seeking providers with whom they can discuss this highly effective HIV-prevention tool. Across the country, directories and locator tools in various forms are helping to link individuals with healthcare providers who will prescribe PrEP and offer comprehensive services, such as counseling to reduce risk behavior and encourage adherence and monthly STI testing for those who use PrEP. [READ MORE]

 

^ Return to Top


World Health Assembly: Here's What you Need to Know (6-1-2016)

Posted June 1, 2016

Click here to view the International AIDS Society announcement.

 

^ Return to Top


NYC Health: Interim Zika Virus Update (5-31-2016)

Posted May 31, 2016

2016 DOHMH Advisory #15: Interim Zika Virus Update

  • One commercial diagnostic laboratory (Quest) now offers RT-PCR testing of serum for Zika virus.
  • For pregnant women and their male sex partners, providers should also call 866-692-3641 to arrange urine RT-PCR and serum antibody testing through the NYC Health Department’s Public Health Laboratory.

Dear Colleagues,

Until recently, Zika virus testing for NYC residents has only been available through the NYC Health Department’s Public Health Laboratory. One commercial laboratory (Focus Diagnostics, a subsidiary of Quest) recently began accepting serum specimens for rRT-PCR Zika testing. Providers should understand that Quest is only performing rRT-PCR on serum, not on urine. Data from CDC, NY State, and New York City indicate that urine is an essential test for the diagnosis of Zika virus infection. The virus is detectable in urine specimens for a longer period than it is in serum, as long as 29 days after symptom onset in urine compared to 7 days for serum. Most Zika cases in New York City have been diagnosed by urine. Additionally, a negative rRT-PCR on urine and/or serum cannot rule out infection and should be verified with antibody testing (serology). For women (symptomatic or asymptomatic) who were pregnant while in an affected area or who have had a potential sexual exposure to Zi ka virus, and for their male sex partners, antibody testing on serum should always be ordered, and rRT-PCR on both urine and serum are recommended.

Therefore, we advise providers:

  1. When sending specimens to Quest, also collect one serum specimen and one urine specimen to send to the Health Department’s Public Health Laboratory for urine rRT-PCR and, if necessary, serology testing.
  2. Call 1-866-692-3641 to complete the testing approval and requisition process. Refer to HAN#7 for Zika virus testing guidelines (http://www1.nyc.gov/assets/doh/downloads/pdf/cd/zika-advisory7.pdf).

Currently, the average turn-around-time from specimens being received at PHL to results being reported to providers is 3 days for serum PCR, 3 days for urine PCR, and 3 weeks for serology.
The effective turn-around-time for your specific clinic may be longer, because some clinical laboratories only send specimens to PHL at designated intervals, and some specimens have problems with labeling, packaging, or requisition forms that require resolution.

For more information on Zika virus, providers are encouraged to visit our website at http://www1.nyc.gov/site/doh/providers/reporting-and-services.page.

 

^ Return to Top


Updates from AETC Program Friends & Colleagues (5-31-2016)

Posted May 31, 2016

Updates from AETC Program Friends & Colleagues are now available by clicking here.

Included are updates on the following:

  • Billing for PrEP and Related Services
  • His Health
  • LGBT Health Training and Certificate Program
  • Collecting Sexual Orientation (SO) and Gender Identity (GI) Data in Health Centers Office Hours: June 1, 2016, 12:00-1:30 PM ET
  • Billing Effectively & Accurately for Integrated Behavioral Health Services (webinar) – June 6, 2016, 2:00-3:00 PM ET
  • Addressing Social Determinants of Health Among LGBTQ Latino(a) Young Adults (webianr) – June 22, 2016, 1:00-2:00 PM ET
  • Trainers of Consumers on Quality Plus (TCQPlus) – June 21-23, 2016, Atlanta, GA
  • Awareness Days

 

^ Return to Top


FDA Approves First Buprenorphine Implant for Treatment of Opioid Dependence (5-26-2016)

Posted May 26, 2016

The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.

To view the FDA New Release, please click here.

 

^ Return to Top


CDC Update: Diagnostic Testing of Urine Specimens for Suspected Zika Virus Infection (5-25-2016)

Posted May 25, 2016

Please note:

  • Healthcare providers must call the NYC Health Department for approval before testing New York City residents for Zika virus infection.
  • Call 1-866-692-3641 from Monday–Friday, 9am–5pm (except holidays), to obtain approval.
  • The Health Department Public Health Laboratory performs rt-PCR testing of both serum and urine specimens.

Summary
On May 13, 2016, the Centers for Disease Control and Prevention (CDC) issued interim guidance (http://www.cdc.gov/mmwr/volumes/65/wr/mm6518e1.htm) that recommends Zika virus rRT-PCR testing of urine collected less than 14 days after symptom onset, along with testing of patient-matched serum samples, for the diagnosis of suspected Zika virus infection (1). The purpose of this Health Alert Network (HAN) health update is to further disseminate information about the interim guidance to clinical and public health professionals.

To download and view a PDF of the CDC Update, please click here.

 

^ Return to Top


Updates from AETC Program Friends & Colleagues (5-23-2016)

Posted May 23, 2016

Updates from AETC Program Friends & Colleagues are now available by clicking here.

Included are updates on the following:

  • Updated Comprehensive Slide Sets: Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents
  • E-Learn Committee Webinar: Caption This! Update on Section 508 Compliance & Captioning Options
  • HIV and Hepatitis Health Disparities Update: May 2016
  • 12th Annual Women & HIV International Clinic Conference (WHICC) Tour
  • An Introduction to the What Works in Youth HIV Website (webinar) – May 26, 2016, 2:00 – 3:00 PM ET
  • HRSA HAB Funding Opportunity Announcements through the Secretary’s Minority AIDS Initiative Fund
  • Trainers of Consumers on Quality Plus (TCQPlus) – June 21-23, 2016, Atlanta, GA
  • Awareness Days

 

^ Return to Top


NYS Clinical Education: Needs Assessment Survey (5-23-2016)

Posted May 23, 2016

Please click here to view the latest update from the New York State Clinical Education Initiative.

Included are updates on the following:

  • Needs Assessment Survey

 

^ Return to Top


NQC Special Announcement: Submit a Joint Application to NQC's New Training (5-23-2016)

Posted May 23, 2016

Please click here to view the special announcement from the National Quality Center (NQC).

 

^ Return to Top


AIDSinfo: At-a-Glance (5-20-2016)

Posted May 20, 2016

The AIDSinfo At-a-Glance News and Features can be viewed by clicking here.

Included are updates on the following:

  • AIDSinfo Apps Provide Easy Access to HIV-Related Information
  • Recent HIV/AIDS News from NIAID

 

^ Return to Top


Presidential Proclamation — National Hepatitis Testing Day, 2016 (5-20-2016)

Posted May 20, 2016

In the United States, hepatitis A, B, and C are the most common types of viral hepatitis — affecting between 3.5 and 6.9 million people and claiming the lives of thousands of our fellow Americans each year. On National Hepatitis Testing Day, we reaffirm the importance of educating people about viral hepatitis, and we encourage individuals at risk for hepatitis B and hepatitis C to get tested. [READ MORE]

 

^ Return to Top


Introducing New Viral Hepatitis Website (5-20-2016)

Posted May 20, 2016

We are pleased to launch a new HHS viral hepatitis website that will support our work across federal agencies and with partners across the nation to fight viral hepatitis. This is an important step in our efforts to raise greater awareness about viral hepatitis prevention, testing, care and – in the case of hepatitis C – cure, among policy makers, healthcare providers, at risk populations, and the public. [READ MORE]

 

^ Return to Top


HIV Training NY: AI Peer Certification Online Exam and Supervisor Evaluation Now Available (5-18-2016)

Posted May 18, 2016

AI Peer Certification Online Exam and Supervisor Evaluation Now Available

Dear Colleague,

The New York State Department of Health AIDS Institute (AI) is pleased to announce the completion of the final pieces of the online application for certification. The online knowledge exam, study guides, and supervisor evaluation are now available.

Peer Certification Knowledge Exams Now Available
Peer Workers who have started an on-line application for AI certification may now take the knowledge exam through their on-line application. When you open the application, you will find a tab on the right side of the screen labeled “Exam.” You can take the exam whenever you are ready. Although you may take the exam at any time, we recommend you complete most or all of the 90 hours of required training before taking the exam. You can access the online application here:
https://www.hivtrainingny.org/Home/PeerCertification

Completing the exam does not mean you are certified yet. Once all requirements are complete and entered into online application, you should click submit on your application to send it to the Certifying Body. The Certifying Body’s Peer Certification Coordinator will notify you when your application is successfully received and will then move on to review by the Peer Certification Review Board. The Board meets quarterly and will hold its first review of applications on June 16th, 2016. Announcements of certification will be made shortly after.

Peer Certification Exam Study Guides Available
The AI has developed Study Guides to help individuals prepare for the Peer Worker certification knowledge exam. The Study Guides are designed for each of the different certification tracks — HIV, HCV, and Harm Reduction. They are available here on our website here: https://www.hivtrainingny.org/PeerCert/StudyGuide

and via the links below:

Study Guide for Certified HIV Peer Worker Online Exam
Study Guide for Certified HCV Peer Worker Online Exam
Study Guide for Certified HR Peer Worker Online Exam

These study guides are optional resources, but provide a comprehensive summary of all the knowledge and skills that AI Certified Peer Workers should have. We expect that applicants who use the study guides will have all the information necessary to successfully complete the exam.

Peer Worker Supervisor Practicum Evaluation Form Now Available On-Line
As described above, all certified Peer Workers must complete a 500-hour supervised practicum with their sponsor agency to gain real life peer work experience and have an opportunity to practice their skills — and to see if peer work is really for them. In conjunction with the online exam launch, the Supervisor Practicum Evaluation Form is available for supervisors of peer workers who seek certification. Supervisors can complete the form and review it with their peers before the peers upload the evaluation into their online certification. The Supervisor Practicum Evaluation Form is intended to convey information about a peer worker’s ability to provide peer services and to apply Core Competencies in a workplace setting. To access the Supervisor Evaluation, click here.

Completing the exam does not mean you are certified. Once all requirements are complete and entered into online application, you should click submit on your application to send it to the Certifying Body. The Certifying Body’s Peer Certification Coordinator will notify you when your application is successfully received and will then move on to review by the Peer Certification Review Board. The Board meets quarterly and will hold its first review of applications on June 16th, 2016. Announcements of certification will be made shortly after.

Questions about the exam, supervisor evaluation or application? Call 631-444-3209 or e-mail Stephen Sebor at stonybrookpeercertification@gmail.com

Additional Questions? Call 518-474-3045 or e-mail Cassandra Kahl at cassandra.kahl@health.ny.gov.

 

^ Return to Top


HIV Training NY: Peer Certification Process: Informational Session Syracuse (5-18-2016)

Posted May 18, 2016

New York State Department of Health AIDS Institute Peer Certification Process – Informational Session in Syracuse

The New York State Department of Health AIDS Institute (AI) is pleased to announce an opportunity for those interested in Peer Certification to learn more about the process and requirements. To become certified, Peer Workers must:

  • Complete foundational/readiness training or submit a personal statement;
  • Complete 90 hours of Peer Worker training from the Peer Worker Course Catalogue;
  • Have a satisfactory supervisor’s evaluation on a 500-hour practicum;
  • Agree to follow the AI Peer Worker code of ethics; and
  • Pass a knowledge exam.

As we near closer to certifying our first round of peers, the AI Peer Certification Team is visiting sites to offer informational sessions on the process and requirements for certification, as well as answer questions for those who are in the process of being certified.

Topic: New York State Department of Health AIDS Institute Peer Certification Process – Informational Session
Date: Thursday, June 2, 2016
Time: 1:00pm- 3:00pm
Location: University United Methodist Church 1085 E Genesee St Syracuse, NY. Free parking on University Ave, designated parking lots only. Bus lines are available. Enter on University Ave, meeting will be downstairs and signs will direct you. Elevator access is available.

A small lunch will be provided from 12:00pm until 1:00pm. In order to attend the lunch hour, you must be registered for the course and email CNYhivcarenetwork@gmail.com to RSVP for lunch by May 30th. If you are joining us for lunch, please arrive promptly at noon.

To register: https://hivtrainingny.org/Account/LogOn?crs=1873

This 2 hour presentation will provide overview of the process and requirements for AIDS Institute Certification of Peer Workers and provide a step-by step walk through of the process for submitting an application for certification. There will be time for Q&A with members of the AIDS Institute Peer Certification Team.

By the end of this webcast, participants will be able to:

  • State at least three benefits of Peer Certification
  • State the three tracks for AIDS Institute Peer Worker Certification (HIV, HCV, Harm Reduction) and who is eligible to apply for certification
  • Recall the purpose of foundational training for Peer Workers and the option of completing a personal statement in lieu of foundational training
  • Identify the core and specialized training requirements for AIDS Institute Peer Worker certification
  • Recall the requirement for signing and uploading the required Code Of Ethics attestation
  • Recall the requirement for completing a practicum or work experience and uploading a satisfactory supervisor evaluation
  • Recall the requirement for passing a knowledge test and state basic features of the testing process
  • Navigate the on-line application system to begin the process of submitting an application for certification
  • Recall resources and trainings that are available online for both peer workers, their supervisors and agency leadership

Intended Audience: Peer workers pursuing AIDS Institute certification, supervisors of Peer Workers, and interested others.

The AI plans to schedule additional informational sessions throughout NYC and upstate. Stay tuned for more opportunities to attend a session near you.

Questions? Call 518-474-3045

 

^ Return to Top


NYS Clinical Education: New CE Courses, This Month in HIV, Treatment for Hepatitis C, Conference, Symposium (5-17-2016)

Posted May 17, 2016

Please click here to view the latest update from the New York State Clinical Education Initiative.

Included are updates on the following:

  • New CE Courses
  • This Month in HIV: HIV Screening and Diagnosis in New York State
  • Treatment for Hepatitis C: New Tests, New Drugs, and New Recommendations
  • Registration Now Open! Testing, Treatment, and Prevention: The Clinician’s Role in Ending the AIDS Epidemic in New York State
  • New York State 2016 HIV Cure Symposium: Connecting Research to Clinical Practice

 

^ Return to Top


Updates from AETC Program Friends & Colleagues (5-16-2016)

Posted May 16, 2016

Updates from AETC Program Friends & Colleagues are now available by clicking here.

Included are updates on the following:

  • The Same, Only Scarier: Cancer Care and the LGBT Communities (webinar) – May 20, 2016, 2:00-3:00 PM ET
  • Addressing the Behavioral Health Needs of Transgender & Gender Non-Conforming Patients (webinar) – June 13, 2016, 2:00 PM ET
  • Paying for PrEP (brochure)
  • Zika Virus Emergency Response Resources
  • Hepatitis C Virus Infection: Morbidity and Mortality Weekly Reports
  • Improvement Advisor Executive Development Program – Cambridge, MA
  • Awareness Days

 

^ Return to Top


NQC Special Announcement: Submit a Joint Application to NQC's New Training (5-13-2016)

Posted May 13, 2016

Please click here to view the special announcement from the National Quality Center (NQC).

 

^ Return to Top


NYS Clinical Education: Needs Assessment Survey (5-12-2016)

Posted May 12, 2016

Please click here to view the latest update from the New York State Clinical Education Initiative.

Included are updates on the following:

  • Needs Assessment Survey

 

^ Return to Top


NYC Health: New Zika Virus Clinical Guidance Available (5-11-2016)

Posted May 11, 2016

2016 DOHMH ADVISORY #11: New Zika Virus Clinical Guidance Available

Please share with your colleagues in Obstetrics/Gynecology, Maternal/Fetal Medicine, Internal Medicine, Family Medicine, Emergency Medicine, Urgent Care, Pediatrics, Neonatology, Infectious Disease and Neurology:

  • Clinical guidance materials are available from the NYC Health Department for evaluation of Zika virus infection in infants and counseling of pregnant women at risk for Zika virus infection.
  • A conference call on Zika virus for prenatal providers will be held on Thursday, May 12, noon-1 PM.

Dear Colleagues,

The New York City Health Department has developed guidance on clinical care for persons with or at risk for Zika virus infection. The following documents are attached, and are also available on our website:

We invite providers who care for pregnant women to participate in a conference call regarding Zika virus infection and pregnancy. The call will provide:

  • Updated information on Zika virus infection and associated birth defects
  • Details about who should be tested and how to obtain testing for these patients
  • An opportunity to ask questions

DATE/TIME: Thursday, May 12, noon
CALL-IN NUMBER: (800) 611 1148
English Call Registration Link: (https://www.surveymonkey.com/r/GD6VS2W)

For additional information on Zika virus, visit: http://www1.nyc.gov/site/doh/health/health-topics/zika-virus.page. You may also call the 866-692-3641 to discuss a specific case or ask questions about testing. We appreciate your continued diligence and cooperation as NYC responds to Zika virus.

The 2016 DOHMH ADVISORY # 11 can be found at https://a816-health30ssl.nyc.gov/sites/nychan/Lists/AlertUpdateAdvisoryDocuments/HAN_ZikaGuidanceDocWithAttachments.pdf

 

^ Return to Top


NQC e-Newsletter: Impact Report on Technical Assistance (5-11-2016)

Posted May 11, 2016

Please click here to view the e-Newsletter from the National Quality Center (NQC).

 

^ Return to Top


HRSA HIV/AIDS Funding Opportunities Announcement (5-10-2016)

Posted May 10, 2016

Please click here to review the Department of Health and Human Services, Health Resources and Services Administration HIV/AIDS funding opportunities.

 

^ Return to Top


NYC Health: Expedited Partner Therapy is an Exception to the Electronic Prescribing Mandate (5-10-2016)

Posted May 10, 2016

2016 DOHMH ADVISORY # 10: Expedited Partner Therapy is an Exception to the Electronic Prescribing Mandate

Dear Colleagues,

The New York State Commissioner of Health has waived the electronic prescribing mandate in situations requiring the use expedited partner therapy (EPT) for chlamydia. Providers can continue to use paper prescriptions for the treatment of sex partner(s) of patients infected with Chlamydia trachomatis until March 26, 2017.

EPT is the practice of providing a chlamydia-infected patient with medication or prescription to treat his or her sex partner(s) without first examining those partners. When EPT is provided in the form of a prescription, it is assumed the patient will deliver this prescription to his or her partner(s) who then fill it at a pharmacy. The New York State Commissioner acknowledges the difficulty in practicing EPT electronically and has allowed for an exception from the electronic prescribing mandate for its practice.

Guidance on how to write EPT prescriptions can be found at
https://www1.nyc.gov/assets/doh/downloads/pdf/std/ept-hcp-pharmacists-brochure.pdf

The New York State Commissioner of Health’s letter can be found at
http://www.health.ny.gov/professionals/narcotic/electronic_prescribing/docs/2016-03-16_blanket_waiver_letter.pdf

The 2016 DOHMH ADVISORY # 10 can be found at
https://a816-health30ssl.nyc.gov/sites/nychan/Lists/AlertUpdateAdvisoryDocuments/2016%20STD-EPT%20Advisory.pdf

 

^ Return to Top


NYS Health Advisory: Bicillin L-A Shortage (5-10-2016)

Posted May 10, 2016

TO: Local Health Department, Community Health Center, Urgent Care, Emergency Medicine, Family Medicine, Infectious Disease, Internal Medicine, Primary Care, Dermatology, and HIV Care

FROM: New York State Department of Health
Bureau of Sexually Transmitted Disease Prevention and Epidemiology

Health Advisory: Bicillin L-A Shortage

On April 29, 2016, the Food and Drug Administration (FDA) reported a national shortage of Bicillin L-A (penicillin G benzathine suspension) due to manufacturing issues. Benzathine penicillin G is the recommended treatment for syphilis infections and is the only treatment option for pregnant women infected with or exposed to syphilis. The FDA is working with the manufacturer to promote product availability and continues to monitor the situation. More information about Bicillin L-A availability may be found at the FDA Drug Shortage Website: http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Penicillin%20G%20Benzathine%20%28Bicillin%20L-A%29%20Injection&st=c&tab=tabs-1.

The Centers for Disease Control and Prevention (CDC) 2015 STD Treatment Guidelines outline the recommended regimens for syphilis along with alternative regimens which are listed below. Treatment with alternative regimens must include close serologic and clinical follow up.

Primary and Secondary Syphilis

Doxycycline 100mg orally twice daily X 14 days OR
Tetracycline 500mg orally four times daily X 14 days

Latent Syphilis

Doxycycline 100mg orally twice daily X 28 days OR
Tetracycline 500mg orally four times daily X 28 days

Until normal supplies of Bicillin L-A are available, prioritize the use of Bicillin L-A for the treatment of syphilis especially in pregnant women infected with or exposed to syphilis.

Call the NYS Clinical Education Initiative’s STD Center of Excellence at 866-637-2342 to access expert medical consultation on diagnosis, treatment and management of syphilis.

Please contact the NYSDOH Bureau of Sexually Transmitted Disease Prevention and Epidemiology at (518) 474-3598 for additional assistance.

Click here to download a copy of this Health Advisory.

 

^ Return to Top


Updates from AETC Program Friends & Colleagues (5-9-2016)

Posted May 9, 2016

Updates from AETC Program Friends & Colleagues are now available by clicking here.

Included are updates on the following:

  • 12th Annual Women and HIV International Clinical Conference (program materials)
  • 7th Annual Infectious Diseases Update 2016 – June 17, 2016, 9:00 AM – 1:00 PM ET, New York, NY
  • Participants Needed! New Online Pilot Course: Supporting Recovery with Medication-Assisted Treatment (MAT)
  • Updated CDC HIV Surveillance Slide Sets, 2014
  • CDC-Funded HIV Testing: United States, Puerto Rico & US Virgin Islands, 2014
  • Awareness Days

 

^ Return to Top


Quick News Update from OMD AIDS Institute (5-9-2016)

Posted May 9, 2016

OMD SCREENSHOT – May 9, 2016

 

^ Return to Top


AIDSinfo: At-a-Glance (5-6-2016)

Posted May 6, 2016

The AIDSinfo At-a-Glance News and Features can be viewed by clicking here.

Included are updates on the following:

  • Updates to the Perinatal Guidelines and the Adult and Adolescent OI Guidelines
  • AIDSinfo Releases New Consumer Fact Sheets and Infographics
  • May 18 is HIV Vaccine Awareness Day
  • May 19 is National Asian and Pacific Islander HIV/AIDS Awareness Day
  • Recent HIV/AIDS News from NIAID

 

^ Return to Top


NYC Health: Bicillin-LA (benzathine penicillin G) shortage (5-4-2016)

Posted May 4, 2016

2016 DOHMH ADVISORY # 9: Bicillin-LA (benzathine penicillin G) shortage

  • Shortages of Bicillin-LA (benzathine penicillin G) reported nationally and expected to resolve by July 2016.
  • Providers should prioritize treatment of pregnant women infected or exposed to syphilis.

Long-acting benzathine penicillin G is the standard treatment for patients infected with syphilis and the only treatment for syphilis-infected pregnant women. Due to the limited availability of this medication, we advise providers to prioritize treatment of pregnant women infected or exposed to syphilis. Additional information on this drug shortage can be found on the CDC’s website at http://www.cdc.gov/std/treatment/drugnotices/bicillinshortage.htm and on the FDA’s website at
http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Penicillin%20G%20Benzathine%20%28Bicillin%20L-A%29%20Injection&st=c&tab=tabs-1.

Providers should continue to report all drug shortages. Information on reporting drug shortages is available at http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm142398.htm.

To download and view a PDF of the advisory, please click here.

 

^ Return to Top


Hepatitis C Kills More Americans than Any Other Infectious Disease (5-4-2016)

Posted May 4, 2016

New CDC studies underscore urgency of hepatitis C testing and treatment, especially for baby boomers

 

^ Return to Top


FDA Publishes Revised Draft Guidance for Developing Direct-Acting Antiviral Drugs for Treatment of Chronic Hep C (5-3-2016)

Posted May 3, 2016

FDA has revised a draft guidance, titled Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Drugs for Treatment.

The purpose of the guidance is to assist sponsors in the clinical development of direct-acting antiviral (DAA) drugs for the treatment of chronic hepatitis C (CHC) from the pre-investigational new drug application (pre-IND) through the new drug application (NDA) and postmarketing stages.

FDA defines direct-acting hepatitis C virus (HCV) antivirals as drugs that interfere with specific steps in the HCV replication cycle through a direct interaction with the HCV genome, polyprotein,or its polyprotein cleavage products.

The guidance addresses the FDA’s current thinking regarding the overall development program and clinical trial designs to support DAA drugs.

The guidance is available on the FDA website.

To read the complete FDA update, please visit https://content.govdelivery.com/accounts/USFDA/bulletins/14713db

 

^ Return to Top


HIV Quality of Care Clinical Advisory Committee Meeting Minutes and Presentations (5-3-2016)

Posted May 3, 2016

The March New York State Department of Health AIDS Institute’s HIV Quality of Care Clinical Advisory Committee meeting minutes and presentations are available by clicking here.

 

^ Return to Top


NYS Clinical Education: New CE Courses, Conference, STD Lunch and Learn & CEI Line (5-3-2016)

Posted May 3, 2016

Please click here to view the latest update from the New York State Clinical Education Initiative.

Included are updates on the following:

  • New CE Courses
  • Last chance to register! New York State 2016 Clinical Conference on HIV and Hepatitis C: Advancing Care through Knowledge, Policy, and Implementation
  • STD Lunch and Learn Series: Congenital Syphilis
  • CEI Line

 

^ Return to Top


FDA Launches Public Education Campaign to Prevent and Reduce Tobacco Use Among LGBT Young Adults (5-2-2016)

Posted May 2, 2016

The U.S. Food and Drug Administration today announced the launch of a historic public education campaign aimed at preventing and reducing tobacco use among lesbian, gay, bisexual and transgender (LGBT) young adults ages 18-24. Of the more than 2 million LGBT young adults in the U.S., more than 800,000 smoke occasionally. The “This Free Life” campaign is designed to specifically reach the occasional or “social” smokers in the LGBT community to help prevent tobacco-related disease and the loss of tens of thousands LGBT lives to tobacco use each year. [READ MORE]

 

^ Return to Top


New PrEP Brochures from CDC: Paying for and Adherence to (5-2-2016)

Posted May 2, 2016

The following new resources are now available from the CDC.

Fact Sheets and Brochures

For more information on PrEP, please visit the CDC website at http://www.cdc.gov/hiv/risk/prep/index.html

 

^ Return to Top


CDC’s New Risk Reduction Tool: Exploring Prevention Options (5-2-2016)

Posted May 2, 2016

In December 2015, at the National HIV Prevention Conference in Atlanta, CDC launched a pilot version of a new tool that provides updated information about the many prevention methods now available. It’s called the HIV Risk Reduction Tool (HRRT). I would like to tell you how we arrived at the new messages contained in the tool and to invite you to help us continue to improve it. [READ MORE]

 

^ Return to Top


Updates from AETC Program Friends & Colleagues (5-2-2016)

Posted May 2, 2016

Updates from AETC Program Friends & Colleagues are now available by clicking here.

Included are updates on the following:

  • Updated AETC Program Design Files and Templates
  • Department of Health and Human Services Implementation Guidance to Support Certain Components of Syringe Services Programs, 2016
  • Health, United States, 2015
  • Retooling Your HIV/AIDS Organization to Compete in the Ever Evolving Healthcare Landscape (webinar) – May 10, 2016, 2:00 – 3:00 PM ET
  • Going Viral: HIV, HCV and Worker Safety in 2016 – June 16, 2016, 8:30 AM – 3:30 PM ET, Westborough, MA
  • Awareness Days

 

^ Return to Top


Shortage of Bicillin-LA (benzathine penicillin G) (4-29-2016)

Posted April 29, 2016

CDC was recently notified of difficulties in obtaining Bicillin-LA (benzathine penicillin G). Benzathine penicillin G is the recommended treatment for syphilis and the only treatment option for pregnant women infected with or exposed to syphilis. The recommended treatments for syphilis are outlined in 2015 STD Treatment Guidelines along with alternative regimens.

For more information on the shortage, see Bicillin-LA (benzathine penicillin G) Shortage.

 

^ Return to Top


May Is Hepatitis Awareness Month (4-29-2016)

Posted April 29, 2016

Each May, many partners across the federal government, including the Department of Health and Human Services (HHS) and its agencies, join with numerous non-federal and community allies to raise awareness of viral hepatitis during Hepatitis Awareness Month. The month-long observance includes national Hepatitis Testing Day on May 19th. [READ MORE]

 

^ Return to Top


WHO Issues Updated HCV Guidelines for Treatment (4-29-2016)

Posted April 29, 2016

Due to the rapid development and evolution of direct-acting viral treatments, WHO issued updated guidelines for the screening, care and treatment of individuals with chronic hepatitis C virus infection at the International Liver Congress [READ MORE].

 

^ Return to Top


NYC Health: Updated Diagnostic Testing for Zika Virus and Interpretation of Results (4-28-2016)

Posted April 28, 2016

2016 DOHMH Advisory #5 (UPDATED): Diagnostic Testing for Zika Virus and Interpretation of Results

  • As of April 28, 2016, the Public Health Laboratory will no longer routinely test specimens submitted for Zika testing from symptomatic patients for dengue and chikungunya viruses by reverse transcriptase polymerase chain reaction (RT-PCR). Clinicians should request RT-PCR testing for dengue and chikungunya viruses through a commercial laboratory.
  • Diagnosis of Zika virus infection often includes testing by both RT-PCR and serology.
  • Some patients will require a follow-up (convalescent) specimen for serologic testing to verify Zika virus infection or determine which flavivirus caused the infection.
  • Call the PAL to arrange all Zika virus testing at 1-866-692-3641.

To read the NYC DOHMH Dear Colleague Letter, please click here.

NYS Zika Virus Information Line: 1-888-364-4723

 

^ Return to Top


NYS Medicaid Update: April (4-27-2016)

Posted April 27, 2016

Dear Medicaid Provider,

The Office of Health Insurance Programs of the New York State Department of Health has approved the release of the April 2016 Medicaid Update.

Please click the link below to download the current edition.

http://www.health.ny.gov/health_care/medicaid/program/update/2016/april_16mu.pdf (PDF)

To see a list of all of the DOH Medicaid Updates, please visit http://www.health.ny.gov/health_care/medicaid/program/update/2016/

 

^ Return to Top


Updates from AETC Program Friends & Colleagues (4-26-2016)

Posted April 26, 2016

Updates from AETC Program Friends & Colleagues are now available by clicking here.

 

^ Return to Top


CDC: HIV Infection & Zika Virus (4-26-2016)

Posted April 26, 2016

To view the article, please visit http://www.cdc.gov/zika/hc-providers/hiv-zika.html

 

^ Return to Top


New CDC Fact Sheet: HIV Among Youth (4-26-2016)

Posted April 26, 2016

  • Youth aged 13 to 24 accounted for more than 1 in 5 new HIV diagnoses in 2014.
  • Young gay and bisexual males accounted for 8 in 10 HIV diagnoses among youth in 2014.
  • At the end of 2012, 44% of youth ages 18 to 24 years living with HIV did not know they had HIV.

For more information, please visit http://www.cdc.gov/hiv/group/age/youth/

 

^ Return to Top


AIDSinfo: At-a-Glance (4-22-2016)

Posted April 22, 2016

The AIDSinfo At-a-Glance News and Features can be viewed by clicking here.

Included are updates on the following:

  • AIDSinfo Education Materials Now Include Infographics
  • AIDSinfo Releases New Consumer Fact Sheets
  • CDC Updates Nonoccupational Postexposure Prophylaxis (nPEP) Guidelines
  • National Library of Medicine Announces Solicitation of Quotations for the 2016 HIV/AIDS Community Information Outreach Projects
  • Recent HIV/AIDS News

 

^ Return to Top


NYC Health: Increase in Drug Overdoses Deaths and Increased Presence of Fentanyl in NYC (4-21-2016)

Posted April 21, 2016

Increase in drug overdoses deaths and increased presence of fentanyl in New York City

 

^ Return to Top


STD Awareness Month: CDC Encourages Everyone to Talk, Test, and Treat (4-20-2016)

Posted April 20, 2016

A special note to the public from Dr. Gail Bolan, Director, Division of STD Prevention, CDC, this STD Awareness Month. April is STD Awareness Month, which gives us the opportunity to talk about sexual health in an inclusive way that speaks to individuals from all walks of life. Sex is a part of most of our lives—but sexually transmitted diseases (STDs) do not have to be one of the “facts of life.” [READ MORE]

 

^ Return to Top


HIV Training NY: Peer Certification Tests Scheduled, Study Guides Available Soon (4-19-2016)

Posted April 19, 2016

New Developments in AI Peer Certification Program  

The New York State Department of Health AIDS Institute (AI) is pleased to announce several important developments in the AI’s Peer Worker Certification effort. To become certified, Peer Workers must:

  • Complete foundational/readiness training or submit a personal statement;
  • Complete 90 hours of Peer Worker training from the Peer Worker Course   Catalogue;
  • Have a satisfactory supervisor’s evaluation on a 500-hour practicum;
  • Agree to follow the AI Peer Worker code of ethics; and
  • Pass a knowledge exam.

The three updates below pertain to the Peer Worker knowledge exam and to the Supervisor Practicum Evaluation Form.

 

Peer Certification Exam Study Guides Now Available

The AI has developed Study Guides to help individuals prepare for the Peer Worker certification knowledge exam. The Study Guides are designed for each of the different certification tracks – HIV, HCV, and Harm Reduction. They are available
here on our websit: https://www.hivtrainingny.org/Home/PeerCertification and
via the links below:

Study Guide for Certified HIV Peer Worker Online Exam

Study Guide for Certified HCV Peer Worker Online Exam

Study Guide for Certified HR Peer Worker Online Exam

These study guides are optional resources, but provide a comprehensive summary of all the knowledge and skills that AI Certified Peer Workers should have. We expect that applicants who use the study guides will have all the information necessary to successfully complete the exam.

 

Peer Certification Knowledge Exams to Be Available On-Line Starting May 2, 2016

Peer Workers who have started an on-line application for AI certification will be able to take the knowledge exam through their on-line application beginning May 1, 2016. When you open the application, you will find a tab on the right side of the screen labeled “Exam.” You can take the exam whenever you are ready after May 1. Although you may take the exam at any time, we recommend you complete most or all of the 90 hours of required training before taking the exam.

 

Peer Worker Supervisor Practicum Evaluation Form to Be Available On-Line Beginning May 2, 2016

As described above, all certified Peer Workers must complete a 500-hour supervised practicum with their sponsor agency to gain real life peer work experience and have an opportunity to practice their skills — and to see if peer work is really for them. In conjunction with the online exam launch, the Supervisor Practicum Evaluation Form will be available for supervisors of peer workers who seek certification. Supervisors can complete the form and review it with their peers before the peers upload the evaluation into their online certification. The Supervisor Practicum Evaluation Form is intended to convey information about a peer worker’s ability to provide peer services and to apply Core Competencies in a workplace setting.

The AI Peer Certification team has been working with peer workers to meet their needs and assist them throughout the certification process. We encourage anyone interested in peer certification to review the important resources at: https://www.hivtrainingny.org/Home/PeerCertification, including:

Peer Certification FAQ

Peer Certification Course Catalog

Peer Certification Code of Ethics

Course Tracker Forms

Core Competencies

 

Additional Questions? Call 518-474-3045 or e-mail Cassandra Kahl at cassandra.kahl@health.ny.gov

 

^ Return to Top


NYS Clinical Education: New CE Courses & Learning Modules, Webinar, Treatment for Hepatitis C, PrEP Payment Options (4-19-2016)

Posted April 19, 2016

Please click here to view the latest update from the New York State Clinical Education Initiative.

 

^ Return to Top


CDC Releases Updated nPEP Guidelines (4-18-2016)

Posted April 18, 2016

The Centers for Disease Control and Prevention (CDC) released Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV, which updates and expands the 2005 U.S. Department of Health and Human Services recommendations for medical practitioners regarding nonoccupational postexposure prophylaxis (nPEP) use for persons in the United States. Updated Occupational PEP Guidelines, which address case management for persons with possible HIV exposure in health care settings, were published separately in 2013. Awareness of nPEP and its availability for both clinical providers and those who are eligible to receive it are critical to ensure that nPEP reaches those who need it most urgently.

For more information, please visit http://stacks.cdc.gov/view/cdc/38856

 

^ Return to Top


Updates from AETC Program Friends & Colleagues (4-18-2016)

Posted April 18, 2016

Updates from AETC Program Friends & Colleagues are now available by clicking here.

 

^ Return to Top


Email Announcement Archives

The HIV Clinical Guidelines Program provides subscribers with email announcements of when new guidelines are posted and existing guidelines are updated.

hivguidelines email announcement archives

hivguidelines Trends, Topics & Updates monthly mailer archives

Subscribe to hivguidelines email announcements

 

^ Return to Top


Hot Topics Archive

Please visit the Hot Topics Archive page.

^ Return to Top